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SUMMARY 
Synthetic pulmonary surfactant consists of phospholipid mixtures, free fatty acids and/or sterols, as well 
as specific protein constructs that mimic the functions of surfactant associated proteins B and/or C. 
Treatment of neonatal respiratory distress syndrome with surfactant replacement therapy consists of an 
invasive technique of endotracheal intubation and administration into the airway. For this reason, a less 
invasive approach such as nebulisation in these frail patients would be beneficial.  
Formulations of synthetic pulmonary surfactants intended for use, require that the in vitro-aerosolisation 
behaviour with regards to optimal particle size generation and conservation of surface tension, are ideal 
in order to maintain proper lung function. The objective of this study was to evaluate the suitability of 
different formulations of a new peptide-containing synthetic pulmonary surfactant Synsurf® during 
aerosolisation in comparison with the natural surfactants, Curosurf® (porcine) and Liposurf® (bovine).  
Synsurf®, was synthesised with and without alterations in key components that included cholesterol       
(1 % and 2 %), palmitic acid (11 %) and tripalmitin (7 %). An extrusion method through polycarbonate 
membranes with different pore sizes was also included during synthesis of the different formulations. 
Surfactants were aerosolised with the use of Aeroneb®Pro vibrating mesh nebuliser and particles 
generated were assessed with a Malvern Zetasizer® and visualised by scanning electron microscopy. 
Surface tension analyses was determined with a Drop Shape Analyser (DSA25).  
The main findings of this study showed that nebulisation of non-extruded Synsurf® formulations as well 
as Curosurf® and Liposurf®, produced a decrease of ± 80 % - 90 % in particle size, that is below the 
desired distribution range of 1 - 3 d.µm for inhaled particles. However, extrusion included in the 
synthesis of Synsurf®, generated larger particles post-nebulisation, within the desired range. 
Nebulisation also significantly influenced the density and viscosity of most Synsurf® preparations and 
natural surfactants. Additionally, an increase in cholesterol concentration showed a marked increase in 
viscosity of Synsurf®.  
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With the exception of the original Synsurf® formulation, nebulisation diminished the surface tension 
lowering ability of all other surfactant preparations. Addition of palmitic acid/tripalmitin and                       
1 % cholesterol to the original Synsurf® formulation showed an overall pronounced reduction in surface 
tension in comparison to other formulations.  
In conclusion, the data of this study indicate that the original formulation of Synsurf® with addition of 
palmitic acid/tripalmitin and low concentrations of cholesterol, aid in the conservation of the surface 
tension properties and ideal particle size generation of the surfactant during nebulisation with a vibrating 
mesh nebuliser.  
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OPSOMMING 
Sintetiese pulmonêre surfaktant bestaan uit fosfolipiedmengsels, vry vetsure en/of sterole, sowel as 
spesifieke proteïenkonstrukte wat die funksies van surfaktant geassosieerde proteïene B en/of C 
naboots. Behandeling van neonatale respiratoriese-nood-sindroom behels 
surfaktantvervangingsterapie, ’n ingrypende tegniek van endotrageale intubasie en toediening in die 
lugpyp. ’n Minder ingrypende benadering soos nebulisering sal gevolglik voordeliger vir hierdie 
tingerige pasiënte wees.  
Formulerings van sintetiese pulmonêre surfaktante wat vir gebruik bedoel is, vereis ideale in vitro-
aërosoliseringswerking ten opsigte van die ontwikkeling van optimale partikelgrootte en die behoud 
van oppervlakspanning ten einde behoorlike longfunksie te handhaaf. Die doel van hierdie studie was 
om die geskiktheid tydens aërosolisering van verskillende formulerings van ’n nuwe peptiedbevattende 
sintetiese pulmonêre surfaktant, genaamd Synsurf®, teenoor die natuurlike surfaktante Curosurf® (vark) 
en Liposurf® (bees) te evalueer.  
Synsurf® is met en sonder veranderings in sleutelkomponente soos cholesterol (1 % en 2 %), 
palmitiensuur (11 %) en tripalmitien (7 %) gesintetiseer. Ekstrusie by wyse van 
polikarbonaatmembrane met verskillende poriegroottes is tydens die sintese van die verskillende 
formulerings toegepas. Surfaktante is met behulp van ’n Aeroneb®Pro- vibrerende “mesh”-
nebuliseerder geaërosoliseer, terwyl die partikels wat ontwikkel is aan die hand van ’n Malvern 
Zetasizer® geëvalueer en deur middel van ’n skandeer elektronmikroskoop gevisualiseer is. ’n 
Druppelvormontleder (Eng. drop shape analyser, die DSA25) is gebruik om oppervlakspanning te 
ontleed.  
Die hoofbevindings van hierdie studie toon dat nebulisering van Synsurf®-formulerings, asook 
Curosurf® en Liposurf® die partikelgrootte met ± 80 % - 90 % verminder het. Dit is benede die verlangde 
verdelingspektrum van 1 – 3 d.µm vir geïnhaleerde partikels is. In die geval van Synsurf®, egter, het 
die ekstrusie tydens sintetisering na nebulisering groter partikels opgelewer, maar steeds binne die 
verlangde spektrum. Nebulisering het ook die digtheid en viskositeit van die meeste Synsurf®-preparate 
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en natuurlike surfaktante aansienlik beïnvloed. Daarbenewens het ’n toename in 
cholesterolkonsentrasie ’n duidelike toename in die viskositeit van Synsurf® getoon. 
Nebulisering het alle sufaktantpreparate buiten die oorspronklike Synsurf®-formulering se vermoë om 
oppervlakspanning te verlaag, verminder. Wanneer palmitiensuur/tripalmitien en 1 % cholesterol by 
die oorspronklike Synsurf®-formulering gevoeg is, was die totale vermindering in oppervlakspanning 
duidelik in vergelyking met ander formulerings.  
Ten slotte dui die studiedata aan dat die oorspronklike Synsurf®-formulering met die byvoeging van 
palmitiensuur/tripalmitien en lae konsentrasies cholesterol daartoe bydra dat die surfaktant se 
oppervlakspanningeienskappe en die ontwikkeling van ideale partikelgroottes behoue bly tydens 
nebulisering met ’n vibrerende “mesh”-nebuliseerder. 
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extrusion with a 5 μm or 12 μm filter). Curosurf® and Liposurf® shown pre- and post-nebulisation. . 53 
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List of Abbreviations 
CHOL   Cholesterol  
CI   Confidence Interval 
COPD   Chronic Obstructive Pulmonary Disease 
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DLS   Dynamic Light Scattering 
DPPC   1,2-Dipalmitoyl-sn-glycero-3-phosphocholine  
ET   Endotracheal Tube 
HMD   Hyaline-Membrane Disease 
IRDS   Infant Respiratory Distress Syndrome 
LB   Lamellar Bodies 
MV   Mechanical Ventilation 
NEB   Nebulised 
NISRT   Non-Invasive Surfactant Replacement Therapy 
NLs   Neutral Lipids 
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PC   Phosphatidylcholine 
PG   Phosphatidylglycerol 
PLs   Phospholipids 
POPC   1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  
POPG   1-palmitoyl-2-oleoylglycero-3-phosphoglycerol  
PS   Pulmonary Surfactant 
RDS   Respiratory Distress Syndrome 
SAP   Surface-Associated Phase 
SD   Standard Deviation 
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SP   Surfactant Proteins 
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ST   Surface Tension 
TEM   Transmission Electron Microscopy 
TM   Tubular Myelin 
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CHAPTER 1: Introduction 
Surfactant replacement therapy (SRT) has been established as an effective and safe therapy for 
premature-related pulmonary surfactant deficiency since the late 1980s.1 Since then, direct intratracheal 
instillation of surfactant has been shown to reduce mortality and morbidity in infants with respiratory 
distress syndrome (RDS) and is the standard mode of administration.1,2 However, there have been 
associated complications that arise from intratracheal instillation which can be divided into two clusters: 
(1) procedural and (2) physiological complications. Procedural complications include the plugging of 
endotracheal tubes, hypoxia-induced bradycardia, hemoglobin desaturation and suboptimal deposition 
(pharyngeal or single lung deposition and suboptimal dosing). Physiological complications include the 
possible occurrence of pulmonary hemorrhages, mucus plug formation, barotrauma, and hyper- or 
hypoventilation causing changes in cerebral blood flow.3 Thus, alternative administration techniques 
have been investigated to reduce the invasive endotracheal intubation or duration thereof. These include 
laryngeal mask delivery, the INSURE method (short intubation followed by continuous positive airway 
pressure), nasopharyngeal instillation, aerosolised preparations and intratracheal catheters. However, 
rapid endotracheal instillation is still the mode of choice to date.4,5  
Non-invasive surfactant replacement therapy (NISRT) by means of nebulisation with the use of jet 
aerosol and ultrasonic nebuliser generators have received ample attention in the past, but showed to be 
inferior/non-beneficial in comparison to endotracheal administration. NISRT demonstrated technical 
and clinical challenges due to its sub-optimal intra-pulmonary delivery and variations in clinical 
effectiveness.6,7 The development of an effective SRT by nebulisation would require the surfactant to 
remain unaltered post-nebulisation and maintain bio-activity with optimal distribution in the distal areas 
of the lung thus highlighting the importance of surfactant composition and particle size generated by 
aerosolisation.8 Recent advances in nebulisation technologies have paved the way for the possibility of 
therapy by aerosolisation. Most recently, vibrating mesh nebulisers have emerged, producing highly 
uniform particles with reduced shear stress on nebulised surfactant which decreases the denaturation of 
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proteins.1 Animal studies indicated a >14% increase of pulmonary deposition when using mesh 
nebulisers compared to the standard jet aerosol generators.4,9 
Particle size generated by aerosolisation is an important factor in pulmonary distribution and many 
deposition studies using glucocorticoids and bronchodilators have indicated that particles should be 
smaller than 5 μm to be able to surpass the upper airway.4 The ideal particle size for optimal distribution 
in the peripheral regions of the lungs is not clearly defined, but the recommended range has been 
established between 1000 nm to 3000 nm.10,11 However, submicron particles may result in less than 
desirable deposition resulting in minimal interaction with the lung surface due to reduced gravitational 
forces and are most likely to be exhaled. Aerosol delivery can be influenced by various factors including 
aerosol characteristics, particle density, patient interface, device selection and ventilation parameters.12 
For the purpose of this study, emphasis is placed on the biophysical properties of a synthetic surfactant 
aerosol generated by a vibrating mesh nebuliser. The feasibility of effective nebulisation administration 
of a novel synthetic surfactant, Synsurf®, with alterations in composition to assist in bio-activity 
preservation after aerosol administration is also investigated. 
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CHAPTER 2: Literature review 
2.1 Structure of the lung 
The uptake of oxygen and removal of carbon dioxide by the respiratory system is essential to maintain 
cellular metabolism and acid-base balance. The respiratory system is illustrated in Figure 2.1, and 
consists of the following organs: nose, pharynx, larynx, trachea, bronchial trees and lungs (containing 
alveolar sacs (alveoli)).13,14 Alveoli, described as small sacs, are shown in the cross section of the lung 
(Figure 2.1 - B).   
 
 
 
 
 
 
 
Figure 2.1: Organs and structures of the human respiratory system. A) Normal lungs, showing the 
organs of the respiratory system, responsible for conducting air to the lungs. B) Shows the respiratory 
zone of the lung bronchioles leading to alveoli.15  
Inhaled air passes through the nose/mouth, into the pharynx, past the larynx and into the trachea, to the 
conduction zone which includes (bronchi, bronchioles and terminal bronchioles), this zone is 
responsible for the movement of air, leading to the respiratory zone (respiratory bronchioles, alveolar 
ducts and alveolar sacs) as shown in Figure 2.1 (B). The respiratory zone is where gas exchange 
occurs.16 Figure 2.2 shows 23 generations of branching within the lung, with each descent into the lungs, 
narrowing, shortening and increase in quantity of structures, allowing for a large surface area                     
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(~ 60 to 100 m2) required for effective gas exchange. The exponential decrease in diameter of each 
section and zone, limits the deposition of inhaled materials. Only particles with a diameter less than 2 
µm are expected to deposit (settle) in the terminal respiratory zone.17  
 
 
 
 
 
 
 
Figure 2.2: Illustration of airway trees marking the conduction and respiratory zones.  Generation of 
descent is shown on the right-side of the sketch (annotated by Z) starting with the trachea = 0. 
Respiratory zone starts with respiratory bronchioles at generation = 16.18  
2.2 Foetal to neonatal lung adaptation 
Intrauterine to neonatal transition is a complex physiological adaptation essential for survival.  Effective 
management and treatment of neonatal pulmonary abnormalities are crucial but remains challenging. 
However, to understand and treat term and pre-term infant lung abnormalities, it is necessary to 
comprehend normal pulmonary development and foetal-neonatal transition.19 Neonatal transition 
entails three key components that include: (1) the clearance of foetal lung fluid, (2) secretion of 
pulmonary surfactant and (3) the onset of consistent breathing.20 Although many factors influence the 
transition from foetal to the neonatal phase, one of the most clinically relevant is the production and 
secretion of surfactant. Pulmonary surfactant (PS) is essential for surface tension reduction, a process 
required for stabilising and inflation of alveoli, thus allowing gas exchanges and contributing to stable 
breathing.13,19,20  
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2.3 Infant respiratory distress syndrome  
Infant respiratory distress syndrome (IRDS) previously known as hyaline-membrane disease (HMD) is 
the most common respiratory/pulmonary disorder in pre-term infants.19 IRDS is characterised by a lack 
of sufficient PS in preterm infants or malfunction in PS in older infants, of different aetiologies (which 
can include a mutation in associated surfactant proteins).19  
In a review article published in the Bulletin of the World Health Organisation, it was estimated that the 
global prevalence of pre-term births in 2005 was 12.9 million (which related to 9.6 % of all births 
worldwide), of which the bulk (85 %) was concentrated in Africa and Asia (collectively 10.9 million). 
Southern Africa showed a high rate of pre-term births of 17.5% (95% confidence interval (CI) = ranges 
from 14.6 % to 20.36 %).21 
Many factors are linked to the risk for developing IRDS, however, with decreased gestation age an 
increased risk and severity of IRDS is observed as shown in Table 2.1.19 IRDS is described as 
progressive and the stages can be clearly distinguished when analysing the radiographic, 
histopathological and clinical manifestations.22 Infant prematurity results in (1) inadequate PS and a (2) 
structurally immature lung, resulting in a “mismatch” of ventilation and perfusion that is reflected in 
the recordings of hypoxia, hypercapnia, acidosis, cell injury and ultimately results in lung injury and 
respiratory failure.22,23 Clinical treatment/management guidelines have received ample attention; 
however, some controversies exist and have not been resolved.23 SRT has been deemed essential in the 
treatment and possible prevention (by prophylactic administration) of IRDS.19,21,23  
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Table 2.1: Incidence of IRDS, related to a decrease in gestational age. The first column indicates the 
gestational age (intervals 24 - 36 weeks) and classification of prematurity in conjunction with the 
incidence of each prematurity category (with relation to overall premature births) and incidence of IRDS 
presenting in neonates at birth or thereafter.19 
2.4 Surfactant replacement therapy  
The first model illustrating the administration of exogenous PS for the treatment of respiratory distress 
syndrome (RDS) arising from prematurity in the rabbit model was shown in 1972 by Enhörning and 
Robertson.24 Since then many prevention and treatment strategies have been developed for treatment of 
infant respiratory distress syndrome (IRDS), this includes SRT, in combination with assisted ventilation 
and supportive care and can include the administration of antepartum glucocorticoids. The possibility 
of administering corticosteroids to stimulate the foetal adrenal cortex and accelerating lung maturity 
has been studied and a decrease in mortality rate is observed.25 However, the long term risks have not 
been evaluated.23 Delivery room stabilisation is essential in all pre-term and term deliveries however, 
some additional stabilisation techniques that include oxygen therapy and positive pressure lung inflation 
is not evidence based and additional studies need to be conducted.19,23 
SRT, is considered the golden standard in the treatment of infants presenting with IRDS. An European 
consensus guideline published in 2013 stated that the optimal time, dose and best preparation of 
exogenous surfactant is unclear, at different gestational ages.23 However, proceeding guidelines (2016) 
concluded that natural surfactants at a higher initial dose in combination with early rescue therapy 
should be instated as standard therapy.26 Recommendations for prophylactic administration of SRT is 
Gestational age 
Classification of 
prematurity 
Incidence in pre-
mature births (%) 
Incidence of IRDS 
(%) 
24 - 25 weeks 
Extreme 5% 
92% 
26 - 27 weeks 88% 
28 - 29 weeks Severe 15% 76% 
30 – 31 weeks Moderate 20% 57% 
32 – 36 weeks Near-Term 60-70% 20-25% 
Stellenbosch University  https://scholar.sun.ac.za
 15 
 
problematic to construct due to controversies in administration based on gestational age5, use of 
stabilising non-invasive respiratory support23 and possible downstream financial consideration.  
Animal and human studies have indicated that early SRT can reduce ventilatory induced lung injury as 
the distribution of exogenous surfactant in the lung is optimised.27,28 However, due to the necessity for 
the use of an endotracheal tube (ET) to administer SRT and mechanical ventilation (MV), ethical 
considerations (due to pain management) and side-effects, an improvement in SRT administration 
techniques are required.5 Currently, rapid instillation, most commonly using endotracheal intubation of 
exogenous surfactant is the only approved mode of administration in IRDS and is routinely followed 
by MV. Complications arising from this intervention can include; acute airway obstruction, 
bradycardia, hypoxia and reduced cerebral blood flow. Prolonged MV can increase the risk of 
ventilator-associated lung injury, chronic lung disease, and pneumonia. With a notable risk of co-
morbidities associated with the use of intubation and MV, the necessity of alternative less-invasive 
administration techniques has increased.23 Minimal and non-invasive surfactant therapy which include 
nasopharyngeal instillation, intratracheal catheters, laryngeal masks and aerosolisation by nebulisation 
have been suggested as an alternative to the standard endotracheal tube instillation. However, lack of 
clinical data and technical challenges arising from these techniques have hampered the routine use of 
alternative modes of administration. Delivery of SRT is under review and many studies have 
investigated the possibility of alternative administration routes; however, to date no true minimal 
invasive SRT is being utilised.5,23 Table 2.2 explores the advantages/disadvantages of alternative 
administration routes being investigated and also includes the traditional administration by endotracheal 
tube instillation.  
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Table 2.2: Summary of established and experimental methods for the administration of surfactant 
replacement therapy. (Adapted from4,5) 
Categories: 
Method of 
administration 
Advantages Disadvantages 
Traditional 
method of 
administration 
Endotracheal tube 
instillation 
Widely used, most 
studies conducted 
applied this method 
Painful, physiological 
effects of MV and 
endotracheal tube. 
Minimal invasive 
surfactant 
replacement 
therapy 
(MISRT) 
Nasopharyngeal 
instillation, laryngeal 
mask, feeding and  
intratracheal catheters 
Less-painful than 
traditional methods, 
supraglottic device, 
easy to use 
Loss of surfactant, 
and lack of trained 
personal 
Non-invasive 
surfactant 
replacement 
therapy 
(NISRT) 
Aerosolisation 
Pain-less, external 
interface, easy to use 
and can be applied 
immediately 
Technical challenges 
2.5 Composition of endogenous pulmonary surfactant 
Healthy lungs contain millions of alveoli (as shown in Figure 2.1), of which the inner walls are coated 
with an aqueous fluid, described as the hypophase, preventing the desiccation (“drying”) of respiratory 
epithelium. As the hypophase is aqueous based, high surface tension is generated, which increases the 
work of breathing and decreases surface area. PS is a membrane based lipid-protein complex, that forms 
a monolayer on top of the hypophase, decreasing surface tension and maintaining alveolar stability at 
expiration thus decreasing ventilation difficulty.14 The composition of human PS (obtained by 
bronchiolar lavage) is well defined however, in the last decade many studies have been carried out to 
clarify the purpose of key compounds within PS.14,29,30  
2.5.1 Composition of pulmonary surfactant lipids  
Type II pneunocytes are responsible for the production and secretion of PS, into the hypophase as 
tubular myelin (TM) as shown in Figure 2.3. After secretion a monolayer is formed, consisting mainly 
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of phospholipids (PL’s), neutral lipids (NL’s) and surfactant-associated proteins (as shown in                   
Figure 2.4).31 It is notable to consider that the exact composition of the monolayer formed at the air-
water interface is dependent on the phase of the respiratory cycle.  
 
 
 
 
 
 
 
Figure 2.3: Represents a simplistic cycle of pulmonary surfactant (PS). Indicated at the bottom of the 
sketch, Type II pneunocyte secreting (via exocytosis) PS packed in lamellar bodies (LB) into the 
hypophase, after secretion, tubular myelin (TM) is formed supplying the surface-associated phase 
(SAP) with lipids and proteins.33 ST = surface tension  
Lipids are the main constituent in mammalian PS, contributing ~ 90% - 95% of total composition, of 
which phospholipids (PLs) are predeominant.30 Phosphatidylcholine (PC) is the most abundant PL and 
specific PC compounds include dipalmitoylphosphatidylcholine (DPPC), a saturated PC, containing 
two saturated acyl chain.30,32 Analytical studies comparing the composition of mouse, rat, rabbit, porcine 
and human PS shows remarkable similarities and differences. However, in all of the species studied, 
PC was found to contribute at least 80% of the total mass of which approximately half consisted of 
DPPC.30 Phosphatidylglycerol (PG) and neutral lipids (NLs) (of which cholesterol is the most prevalent) 
are present in relatively large quantities, contributing significantly to surfactant lipid composition (as 
shown in Figure 2.4).34 Many other species of PC (phosphatidylserine, phosphatidylinositol) and neutral 
lipids (cholesterol esters, diglycerides, triglycerides) are present in lower quantities.32,34  
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Figure 2.4: Shows the typical composition of mammalian pulmonary surfactant, with percentages 
represented as a total of the surfactant mass analysed. Indicated in green, yellow and orange, the total 
lipid composition (PC = Phosphatidylcholine, PG = Phosphatidylglycerol, PL = Phospholipids, Chol = 
Cholesterol, NL = Neutral lipids). Surfactant protein composition is shown in red, indicating surfactant 
proteins (SP) (A, B, C, D).32 
2.5.2 Pulmonary surfactant-associated proteins  
Surfactant proteins (SP) account for approximately ~ 5 % to 10 % of the total weight of PS in humans.30 
Four surfactant proteins (SP), have been identified, this includes SP-A, SP-B, SP-C and SP-D (as shown 
in Figure 2.4).  SP-B and SP-C are hydrophobic proteins, expressed by type II cells in the mature lungs 
and accelerate the adsorption and stabilisation of the monolayer (surface active film), responsible for 
reducing of surface tension.1,35 SP-D and SP-A are collagen based calcium dependent lectins, also 
known as collectins, involved in pulmonary immunity. By weight SP-A is the most abundant surfactant 
protein, and is capable of binding lipids, type II pneunocytes and foreign surfaces (e.g. 
microorganisms).36 Surfactant proteins play prominent roles in surfactant surface behaviour as well as 
in immune defence and particle clearance however, SP-B and SP-C is clinically the most relevant with 
regards to the facilitation of surface tension reduction.32,36,37  
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2.6 Role of lipids in pulmonary surfactant 
Differences in attractive forces between molecules at the air-water interface, leads to high surface 
tension, which resist the expansion of surface area. PS forms a surface active monolayer of 
approximately 0.8 – 5 nm that actively decreases the surface tension from ~70 m/Nm to near zero values 
at physiological tempratures.1,19,38 
2.6.1 Lipid monolayer structure  
The biophysical functionality of the monolayer formed by PS is dependent on its composition. Lipids 
are responsible for the formation of the surface active film at the air-water interface and additionally 
provide a matrix for surfactant structure assembly31,32 (As shown in Figure 2.5).  The monolayer formed 
at the air-water interface is additionally dependent on the concentration of PL’s, as higher 
concentrations lead to less water molecules exposed to the air, thus lower surface tension. Hydrophilic 
head groups are orientated towards the “water phase” and hydrophobic acyl groups (on DPPC 
molecules) are orientated towards the “air phase”.30,31 
Lowering in surface tension decreases the energy needed to enlarge the area during inspiration. Lipid 
and protein components of surfactant can contribute to the biophysical function by either, reducing 
surface tension like DPPC or assisting in spreading/adsorption of PS’s.  Lipids show different levels of 
molecular ordering and mobility, dependent on temperature. This is important when considering the 
transition of a membrane from a gel phase (ordered state) to a liquid phase (fluid state), when thermal 
temperature increases or decreases.39 The temperature at which an equilibrium exists between gel and 
fluid phase is deemed the melting temperature (Tm). For the saturated phospholipid DPPC, the melting 
point is high (Tm = ~ 41°C) and for unsaturated PC species i.e. 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) the melting temperature is low (Tm = ~ -3°C).39-41 
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Figure 2.5: Schematic presentation of pulmonary surfactant adsorption to the air-water interface. The 
movement (by diffusion) of surfactant bilayer (vesicles) structures through the surface-associated phase 
to the air-water interface. Hydrophobic surfactant proteins SP-B and SP-C (as shown), stabilise the 
fusion of the bilayer vesicle to the air water interface.33  
As shown in Figure 2.4, PS is a mixture of complex lipids, with a range of melting temperatures, co-
existing in liquid and gel phases and presents as a monolayer (at the air water interface) or a bilayer 
structure within the surface associated phase as shown Figure 2.5. The monolayer formed at the air-
water interface, serves as a barrier between the environment and lung epithelium. The fusion of the 
double layer structure to the surface (to produce a surface monolayer) is facilitated by interactions 
between PL’s and surfactant proteins (SP-B and SP-C). Additionally, SP-B and SP-C, modulate PL 
permeability, increasing PL flow.42 Although the main PL compound in endogenous PS is DPPC, a 
significant proportion of PL’s are unsaturated PC (~ 20 %) and neutral lipids, mainly cholesterol              
(~ 8%), with melting temperatures below 41°C. This complex mixture of lipids allows native surfactant 
with a high concentration of DPPC (~ 45 %) to have a transitional (ordered/gel ⇄ fluid/liquid) 
temperature close to 37°C.30,31,34,43 
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The presence of cholesterol might change the packing properties of lipid membranes in PS as the 
addition of cholesterol has a profound effect on the ordered and fluid state of the membrane. Cholesterol 
disrupts the highly ordered phase membrane, leading to a more fluid state and orientates the fluid phase 
membrane, thus decreasing fluidity.31 Moreover, cholesterol has a profound effect (even at low 
concentrations) on the order and adherence properties of monolayer formation, actively lowering the 
transition temperature of the phospholipid mixture.30,31 Other effects have been described which include 
increased lipid vesicle adsorption at the air-water interface and enhancement of re-spreading and 
stabilisation of the interfacial monolayer.39 In addition, studies also show that the lateral phase 
separation can be achieved independent of the presence of SP, and dependent on key lipid components 
including cholesterol.31 However, an increase in cholesterol concentration is linked to the inhibition of 
bilayer rearrangement and prevents obtainment of low surface tension values.44 Other minor lipid 
components, found in mammalian PS, might contribute to maintain a low surface viscosity thus 
enabling effective spreading. This is an important consideration when developing an exogenous 
surfactant as preparations with lower surface viscosity are preferred for ET administration.39 
2.6.2 Interfacial film properties 
Interfacial film formation includes the adsorption of the lipids and proteins mixture to the air-water 
interface. The compression a DPPC-enriched monolayer that is formed, is often referred to as 
“squeezing-out” of non-DPPC components.40 DPPC is the surface-active component, and is active in 
reduction of surface tension (from ~ 70 mN/m) to near-zero values at end-expiration.30 The ability of 
DPPC in formation of a tight and orderly packed monolayer is due to the lack of double bonds 
(saturated), which leads to high resistance against collapse.29,30 Studies conducted with a captive bubble 
tensiometer, illustrated that DPPC films could reduce surface tension to less than ~2 mN/m and the 
surface area could be maintained for extended periods of time before returning to equilibrium.45 
However, due to the high melting temperature of DPPC, formation of a monolayer is slow and therefore,  
isolated use of DPPC as surfactant replacement is not feasible and the presence of other lipid 
components that include unsaturated PC and cholesterol is essential.30 On the other hand unsaturated 
PC is not as effective in the formation of a monolayer as the chains are bent (due to double bonds), 
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leading to less dense packing conformation.43 PG accelerate the adsorption thus aiding in rapid 
reduction of surface tension to low (near 0) values. However, film generated with only unsaturated PC 
(thus lacking DPPC) show an inability to reduce surface tension to low near 0 values (~15 – 20 mN/m) 
and return the equilibrium as soon as dynamic compression is stopped.39 From this it can be concluded 
that the combination of DPPC and PG is required for optimal functionality (interfacial film formation). 
However, it has been stated that in the absence of hydrophobic lipoproteins (like SP-B and SP-C) or an 
adsorbance-assistance factor, adsorption will be insufficient and/or at a notable decreased rate.43  
2.7 Natural derived vs synthetic pulmonary surfactant 
Exogenous surfactant is roughly divided into 2 main groups, which includes (1) animal “natural” 
derived surfactants and (2) synthetic surfactants (contains proteins or peptides). All natural and 
synthetic surfactants commercially available are DPPC based.46,47 A few examples of each group are 
shown in Table 2.3. It is important to note that not all exogenous surfactants listed are commercially 
available (some have been discontinued as shown by * moreover, numerous comparative studies have 
been conducted with the majority of the surfactants shown in Table 2.3 (below).  
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Table 2.3: Natural and synthetic surfactants. Information is displayed on the tradename, generic name, 
classification based on composition, source of material, concentration of PL’s and manufacturing 
company (with location) of commercially available and preparations in development.30,32,39,46-48 
(*Discontinued) (**Biophysical analysis at a PL = [25 mg/mL])48 
Brand /Generic 
Name  
Preparation 
Animal 
Source 
Concentration 
PL mg/mL 
Manufacturing 
company 
Animal derived surfactants (Porcine and Bovine) 
Alveofact® 
(Bovactant) 
Derived from lung lavage Bovine 40 mg/mL 
Boehringer Ingelheim 
Co., 
Ingelheim, Germany 
Curosurf® 
(Poractant) 
Derived from animal lung 
tissue 
Porcine 80 mg/mL 
Chiesi Pharmaceutici 
SpA (Parma, Italy) 
Infrasurf® 
(Calfactant)  
Derived from lung lavage Bovine 35 mg/mL 
Forest Laboratories, 
Inc., Missouri, USA 
Liposurf® Derived from lung lavage Bovine 27 mg/mL 
BLES Biochemicals 
Inc., Canada 
Survanta® 
(Beractant) 
Derived from animal lung 
tissue and supplemented 
Bovine 25 mg/mL 
Abbott laboratories, IL, 
USA 
Protein- free synthetic surfactant 
*Exosurf® 
(Colfosceril 
palmitate)  
Protein-free  (only lipids) - 13.5 mg/mL 
GlaxoSmithKline, 
Uxbridge, Middlesex, 
UK 
*ALEC® 
(Pumactant) 
Protein-free   (only lipids) - 25 mg/mL 
Britannia 
Pharmaceutical, Redhill, 
Surrey, UK 
Synthetic surfactants containing peptides and recombinant proteins 
CHF5633  (SP-B 
and SP-C 
analogue) 
SP-B and SP-C enriched 
synthetic surfactant 
- **80 mg/mL 
Chiesi Pharmaceutici 
SpA (Parma, Italy) 
*Surfaxin® 
(Lucinactant) 
Peptide-containing (novel 
KL4 peptide) 
- 30 mg/mL 
Discovery Laboratories, 
Warrington, 
Pennsylvania, USA 
Synsurf® 
Poly-L-lysine and poly-L-
glutamic acid construct 
- 60 mg/mL Innovus, RSA 
Venticute® (rSP-
C surfactant) 
Recombinant    SP-C 
protein 
- 50 mg/mL 
Nycomed GmbH, 
Konstanz, Germany 
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2.7.1 Animal derived “natural” surfactants  
Natural derived surfactants differ significantly from each other however, all showcase similar 
morphology to human surfactant and can be classified by: (1) Origin, most natural surfactants are 
extracted from bovine or porcine sources, (2) extraction, by means of bronchiolar lavage or minced 
tissue, and (3) addition of compounds to natural PS (supplementation) that can include PL’s and neutral 
lipids (NL’s).47  
Natural surfactants can be produced by bronchiolar lavage or minced tissue extraction; however, a 
decreased risk of deactivation of surface-active properties (of extracted surfactant) by plasmatic and/or 
tissue compounds is observed when isolated by bronchiolar lavage.32,47 Curosurf® is a porcine lipid 
extracted surfactant from minced lung tissue, with a final phospholipid concentration of 80 mg/ml 
(Table 2.3). It consists of 99 % PL’s which represents the highest concentration of PL’s for an animal 
derived surfactant and 1 % apoproteins (SP-A and SP-B).46,49 During the manufacture of Curosurf® an 
additional purification step (gel-liquid chromatography) is added to remove NL’s from the mixture, 
thus allowing for a higher concentration of polar lipids.49 Survanta® (Beractant) is an example of a 
bovine minced lung extract with supplemented with DPPC, free fatty acids (~ 5.6 % to 14 %) and 
triglycerides (~ 2 % to 7 %).38,47 It stands to reason that even with careful preparation of natural 
surfactants, differences in biochemical composition can occur (possibly due to differences in source of 
materials), thus some natural preparations are supplemented, mostly with DPPC and palmitic acid.39 
Many clinical studies with mortality as the main comparative outcome, have been conducted comparing 
natural surfactants with each other. However, due to poor enrolment (inadequate sample size) an 
increased risk of type-2 errors (false negative) is observed.50 As shown in Table 2.3 natural surfactants 
differ significantly from each other with regards to composition, reflecting differences in the therapeutic 
effects of each preparation. In a recent randomized clinical trial in Iran, Curosurf® and Survanta® were 
compared and although no differences could be identified with regards to complications arising from 
treatment, Curosurf® decreased the need for endotracheal tube (ET) and continuous positive airway 
pressure (CPAP).51  
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It is known that Curosurf® [PL’s = 80 mg/mL] compared to Survanta® [PL’s = 25 mg/mL] shows a 
significant decrease in need for re-dosing when administered at an initial dose of 200mg/kg.47,52 
Although many studies have compared natural surfactants indicating differences in primary outcomes 
(e.g. need for re-dosing), no differences in the secondary outcomes, which include; occurrence of 
chronic lung disease, period on MV and mortality, were observed.39 
2.7.2 Synthetic surfactants  
Synthetic surfactants can be subdivided into (1) protein-free synthetic surfactants, (2) protein analogue 
containing synthetic surfactants and (3) synthetic peptide-containing surfactants. Composition of 
synthetic surfactants are carefully planned and surfactant mixtures with a decreased DPPC content 
prove useful in maintaining surface activity even at concentrations below that of natural surfactant.39 
The addition of specific anionic PL (this includes PG), are essential for promoting optimal surface-
activity, and most surfactants (natural and synthetic) are DPPC:PG based.30,32,39 Another 
additive/supplement commonly observed in natural and synthetic preparations is palmitic acid (PA). 
Initial adsorption and re-spreading of surfactant is accelerated by PA, but it is cleared from the air-space 
rapidly, and does not contribute to the long-term stability of the film. However, the action of PA could 
potentially assist in rapid action of nebulised preparations, as slow onset has been a concern in previous 
studies.53 Protein-free synthetic surfactants also known as “old synthetic surfactants” include Pumactant 
(ALEC®) which consists predominantly of dipalmitoylphosphatidylcholine (DPPC) and 
phosphatidylglycerol (PG) and Colfosceril palmitate (Exosurf®), which is no-longer commercially 
available (as shown in Table 2.3).  
Protein and peptide containing synthetic surfactants also named “new generation synthetic surfactants” 
include (but is not limited to), CHF5633, Lucinactant (trade name: Surfaxin®), rSP-C surfactant 
(Venticute®) and Synsurf®. The addition of peptides and proteins to PL’s is in order to mimic the 
function of SP-C and/or SP-B.  
CHF5633 is a synthetic surfactant containing a phospholipid mixture of DPPC:POPG 1:1 (w/w) with 
both an SP-B and an SP-C analogue. CHF5366 showed great tolerability and efficacy in animal and 
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human (Phase 1) studies54 with additional resistance to deactivation by albumin in comparison to 
Curosurf®.48 A related aspect to consider is that the PL concentration of CHF5633 and Curosurf® are 
the same (80 mg/mL), but most studies evaluating the biophysical properties of these surfactants, diluted 
the preparations to lower concentrations.48,55 Recently developed Surfaxin® contains a KL4 peptide, 
believed to mimic the function of SP-B and can be produced in large quantities.56 It must be noted that 
most synthetic surfactants can be used at room temperature; however, Surfaxin®, is a gel at room and 
body temperature and requires heating in a water bath for 15 min at 44°C, which might have led to its 
discontinuation. Moreover, nebulisation attempts with a commercially available vibrating mesh 
nebuliser (available for purchase at pharmacies or online) showed clogging indicating that the Surfaxin® 
preparation was suboptimal for the equipment, due to high viscosity of the preparation.57  Presently a 
KL4 containing preparation intended for aerosolisation (Aerosurf®) in combination with a new 
aerosolisation technology (capillary aerosol generator), is being developed by Discovery Laboratories 
(Warrington, Pennsylvania, USA). Initial animal studies with Aerosurf®, administered by endotracheal 
tube or aerosol administration (via only capillary aerosol generator) have indicated similar results with 
regards to improvement of acute lung injury.58  
Venticute® contains synthetic lipids (DPPC, PG and PA) with the addition of recombinant SP-C, 
produced by SP-C expressed bacteria.39 Synsurf® on the other hand is a novel synthetic peptide 
containing surfactant, that consists of DPPC and PG, complexed with a poly-L-lysine and poly-L-
glutamic acid construct that displays cationic and hydrophobic characteristics. The rational behind this 
is that poly-L-lysine interacts with the PL bi-layer and provides some structural and/or functional 
properties, similar to SP-B in native (human) surfactant. Moreover, the overall positive characteristics 
of poly-L-lysine could possibly also mimic SP-C in a similar fashion. In a rabbit model of surfactant 
depletion the ability of Synsurf® to increase oxgenantion by effectively reducing pulomonary shunt was 
establised.59,60  
Both natural and synthetic surfactants are effective as prophylactic and rescue therapy in the treatment 
of IRDS. However, natural surfactants shows superiority with regards to decrease in mortality and 
ventilatory requirements61, but a comparison of mortality (due to IRDS), between “new – generation 
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surfactants” i.e. Lucinactant®, Survanta® and Curosurf® are nevertheless similar.61,62 Moreover, 
complications observed in neonates treated with natural surfactants were found to be similar to those 
treated with synthetic surfactants. However, the therapeutic effects differed amongst preparations 
used.62 To clarify these findings a large-scale, randomized clinical trial will provide the long sought 
after answers concerning safety and efficacy, although it may be a difficult and even near impossible 
task.61  
The efficacy of protein-free synthetic surfactants and commercially available natural surfactants have 
been investigated in many randomized controlled trials, showcasing the ability to reduce mortality and 
morbidity arising from IRDS. In the clinical setting however, animal derived surfactants are being 
utilised more often due to superiority over protein-free synthetic surfactants.4,47,61,62 This has been 
attributed to the presence of surfactant-proteins aiding in adsorption, with a fast onset of action. 
However, studies including recombinant-protein and peptide-containing surfactants vs natural 
surfactant have indicated no significant difference in primary outcomes which included mortality and 
chronic lung disease at 36 weeks.63  
2.8 Challenges of non-invasive surfactant replacement therapy (NISRT) by 
aerosolisation  
Effective delivery of NISRT is dependent on an amalgamation of factors that include; ventilatory 
parameters, airway physiology, preparation (drug) composition and aerosolisation device. These factors 
contribute to the optimal and uniform distribution of surfactant in the lungs.   
2.8.1 Aerosol delivery  
Aerosols are defined as any suspension, which include liquids and solids, dispensed in a carrier gas.64 
Two main technologies are currently utilised for the aerosolisation of liquid suspensions, (1) pressurised 
meter dose inhalers (pMDI's) and (2) nebulisers. Nebulisers can use compressed air or atomised energy 
to produce a dense mist and will be discussed later in this section. 
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The administration of dry powdered (solid) surfactant formulations are being investigated and thus far 
animal studies have generated promising results in the treatment of acute RDS with severe PS 
dysfunction.65 Some natural derived (bovine) surfactants have been freeze-dried to prolong shelf life; 
however, all suspensions available for the treatment of IRDS are re-suspended in saline and not 
administered as a powder. For the purpose of this study only liquid formulations were investigated. 
The efficacy of an surfactant administered by aerosol is dependent on the dose deposition at the site of 
action (alveoli), and distribution within the lungs.11 Aerosol deposition is divided into “stages”, 
referring to the anatomical location and mechanism of deposition within the airway, this includes (1) 
inertial impaction, (2) gravitational sedimentation and (3) diffusion. Additionally, deposition is 
dependent on the particle settling velocity (described by aerodynamic diameter (µm) of particles in an 
aerosol).  
Aerodynamic diameter for a particle suspended in air is a hypothetical diameter of a sphere that entails 
the same density and settling velocity as the particle being investigated. If the particle under 
investigation has a smooth spherical shape the aerodynamic diameter, is close or equal to the actual 
diameter. Aerodynamic diameter is used to directly compare the settling behaviours amongst aerosols 
that might contain particles of non-spherical shape.9 However, analysis techniques using high-airflow 
conditions, are less applicable for imitation of neonatal breathing conditions66, thus analysis of the 
actual particle diameter of by means of laser diffraction is frequently used. 
Table 2.4 shows the “stages” or mechanism of deposition with the indicated particle sizes, expected to 
deposit in the various areas of the airway. Larger particles (5 µm – 10 µm in diameter), are expected to 
deposit in the upper respiratory tract (trachea and bronchi) by means of impaction, due to the turbulent 
and high air velocity associated with aerosolisation. Impaction is an optimal site for drug deposition in 
the treatment of asthma and chronic obstructive pulmonary disease (COPD). Sedimentation (shown as 
the secondary “stage”) is due to a decrease in velocity of air in the secondary bronchus and bronchioles, 
with particles typically ranging from 1 µm – 5 µm in diameter. At alveolar level diffusion is believed 
to be the predominant mechanism of deposition (due to minimal air velocity) of aerosolised 
preparations, for particles larger than 0.5 µm in diameter.11 Particles smaller than 0.5 µm are expected 
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to be expelled upon exhalation however, this is based on healthy airway geometry.67 Neonates show 
low tidal volumes and high respiratory rates, in combination with smaller airways, shortening the 
particle’s residence time, thus deposition by sedimentation (requiring sufficient time to settle due to 
gravitational force) and/or diffusion need to be investigated via deposition studies11,66,67 however, due 
to the inability to use radiolabels in the neonate population, data is limited. Although the aerodynamic 
diameter of particles are essential for distribution studies, other factors which include particle geometry, 
morphology and surface properties (surface activity), should be considered in the development of 
preparations for NISRT.4,7,68 For the development of NISRT focus is placed on diffusion (third stage of 
deposition) and particles with a diameter of less than 2.µm. Brownian motion (diffusion) plays a crucial 
part in distal lung deposition and is more applicable for particles <1 μm.65,69 Modelling of turbulent 
flow in the human lung have shown uniform particle deposition with larger quantities of 1 µm in 
comparison to particles of 5 µm and 10 µm in diameter.70 The involvement of each “stage” is dependent 
on many factors that include: patient factors and ventilation, biophysical properties of the aerosol and 
airway anatomy.71 Consideration of aerosol deposition mechanics are essential, since the objective of 
NISRT is to deposit sufficient amounts of  exogenous surfactant in the distal areas of the lung. However, 
precision physiochemical planning with regards to the size of particles are required as the respiratory 
zone is protected from deposition by extensive branching as shown in Figure 2.2. With a decrease in 
diameter of conduction and respiratory zones, an increased risk of premature deposition in upper 
respiratory tract is expected.9,68,71  
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Table 2.4: The three “stages” of particle deposition. Indicated in the central column are and the mean 
particle diameter sizes of particles (expressed = µm), that will deposit in the indicated anatomical 
structures of the respiratory tract (right-handed column).69 
Mechanism Particle size (diameter in µm) Anatomical structures 
Impaction 5 - 10 Trachea and primary brochus 
Sedimentation 1 - 5 Secondary bronchus and bronchioles 
Diffusion  
(Brownian motion) 
1 – 0.5 Alveolar sacs 
 
2.8.2 Patient factors 
The application of NISRT in pre-term infants can be challenging due to small tidal volume combined 
with low inspiratory flow and possible irregular respiratory rates and high risk of obstruction due to 
narrow upper and lower airways.68 The application of MV in combination with aerosol SRT is favoured 
as the inspiratory time can be significant increased with a reduction in respiratory rate.4,68 However, 
MV is invasive and in addition not always considered for spontaneously breathing infants. Additionally, 
standard ventilatory care includes the delivery of heated and humidified air. With the application of 
humidified and heated air an increase in particle size (leading to impaction) and ± 40% decrease in 
aerosol lung deposition was observed.66 Additional challenges i.e. patient optimal positioning due to 
low birth weight and physical conformation of equipment with patient interface which is challenging 
and can lead to additional upper airway and gastric deposition of aerosolised surfactant. Most studies 
conducted using pre-term infants treated with MISRT and NISRT only included patients from 28 
weeks.4 
2.8.3 Choice of nebuliser 
Particle size is influenced by the device used for aerosolisation, this can be demonstrated by the mean 
diameter of particles generally produced by different nebulisers. Thus the choice of nebuliser is key, 
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and currently four major types of nebulisers are being considered for NISRT. Ultrasonic nebulisers 
produce larger particles ranging from (0.5 µm to 3.0 µm) in diameter, depending of the frequency 
acoustic wave generated by the piezoelectric crystal. However, due to the risk of denaturing proteins 
within surfactant preparations, ultrasonic nebulisers are not generally considered for NISRT.4 On the 
other hand jet nebulisers break liquid into droplets with the use of high velocity air and particles exposed 
to the interface/mouth piece can be regulated by a baffle, which will return larger particles to the 
preparation pool. These nebulisers are cost effective when only considering the device; however, as a 
large portion of the surfactant sample applied is lost due to residence within equipment, efficacy of jet 
nebulisers are low when administering surfactant. Moreover, the diameter of droplets generated by jet 
nebulisers is dependent on characteristic of the liquid (viscosity and surface tension) and the interface 
of the nebuliser itself which includes airflow and diameter of the attached nozzle. A study conducted 
using a jet nebuliser illustrated that only ± 1% of drug dose reached the distal regions of the lung.7  
The recently developed vibrating mesh (membrane) nebulisers, produce particles through a mesh by a 
vibrating action of the piezoelectric plate.12 Advantages of this technology include, smaller interface, 
silent operation, reduction in aerosol dilution and the generation of uniform particles. The reduction of 
shear stress on the preparation allows for nebulisation of proteins and other fragile molecules.9,72 
However, vibrating mesh nebulisers are not compatible with viscous liquids as clogging is of concern.73-
75 In another development, Discovery Laboratories introduced capillary aerosol generating technology 
(CAG), intended for the use in conjunction with Aerosurf®.4 Although this method of aerosol generation 
is known, the technology was not available for analysis at the time of this review.  
2.8.4 Aerosol deposition studies 
The first trial reporting the use of a synthetic surfactant using nebulisation was published in 1964. DPPC 
was nebulised with a jet generator and introduced into the incubator however, no clinical relevant 
beneficial effects were observed but it could be concluded that for aerosolisation the preparation would 
need to be monodisperse (uniform in mass and morphology in the dispersed phase) and particles no 
larger than 1 µm in diameter.76 Although many studies have been conducted with the use of an array of 
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nebulisers and commercial/experimental exogenous surfactants, to date no nebulised surfactant is being 
utilised in the treatment of IRDS.5  
Animal studies comparing direct tracheal instillation to nebulisation have reported mixed outcomes.5 
However, a study indicated that Survanta® showed an equal and superior efficacy when nebulised 
compared to tracheal instillation of animal bronchiolar lavage derived surfactants.77 This is a clear 
indication that composition and delivery are closely interlinked and modulate the interaction of 
surfactant with the pulmonary environment independent of the surface active component and 
concentration in the preparation. Although limited studies are available comparing nebulised surfactant 
in the treatment of IRDS, the findings and outcomes of these studies have provided essential information 
for the development of more effective preparations.4 Studies evaluating the effect of Curosurf® 
administered by nebulisation with the addition of CPAP showed no changes in the period on MV or 
duration of CPAP compared to infants only receiving CPAP. This could be indicative for the need of 
aerosol preparation refinement.53 An open-label pilot study conducted with Aerosurf® nebulised with a 
vibrating mesh nebuliser showed good tolerability and feasibility of administration. Although the study 
did not include a control group, the primary outcome was to assess the viability of the method of 
administration. The particles generated maintained bio-activity (i.e. ability to reduce surface tension), 
post-nebulisation.56 
2.8.5 Physiochemical conditioning of synthetic surfactant mixture 
The development of a synthetic surfactant intended for nebulisation, could provide a safe, non-invasive 
alternative to conventional SRT. However, physiochemical conditioning with regards to the surfactant 
composition (formulation) needs to be investigated as this, in combination with patient factors and 
device selection will influence the deposition and activity of NISRT.12 Modification and design of an 
aerosol for optimal functionality (termed aerosol conditioning74), includes aspects such as the (1) 
composition, (2) particle size generated, (3) preservation of bio-activity and (4) lower preparation 
viscosity74 (liquid consistency), to avoid clogging of nebulisation equipment. Thus for successful 
application of NISRT, DPPC (surface-active compound) and assisting compounds (e.g. cholesterol, 
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palmitic acid and peptides) particles ideally should range from 0.5 µm to 2 µm65 and must rapidly 
deposit to form a DPPC-rich monolayer.32  
2.9 Study Rational 
The main purpose of this study was to evaluate the suitability of a synthetic pulmonary surfactant, 
Synsurf® for aerosolisation with additions in composition, to aid in the bioactivity of particles generated 
by nebulisation. Additionally, Synsurf® (a synthetic surfactant), was compared to natural (animal 
derived surfactants), based on key considerations for the development of aerosol delivery of SRT. Due 
to a lack of information regarding development of a synthetic lung surfactant intended for nebulisation, 
biophysical properties need to be defined that include: viscosity of samples (relating to compatibility 
with nebulisation equipment), surface activity and particle size after nebulisation, thus leading to the 
aims of this study.  
2.10 Aims   
As part of an on-going development program of a novel synthetic peptide-containing surfactant, 
Synsurf® (Stellenbosch University Patent No. 2012/06987), we want to develop and optimise the 
composition of this product for non-invasive administration of SRT i.e. 
1. Development of an ideal formulation of synthetic surfactant with regards to different 
concentrations of phosphatidylglycerol (PG), the disaturated phospholipid 
dipalmitoylphosphatidylcholine (DPPC), cholesterol, tripalmitin and palmitic acid for 
nebulisation.  
2. Establish nebulised liposome stability with age, size, surface tension properties and viscosity 
of these preparations. 
Results obtained can contribute to development of an aerosolised synthetic surfactant for use in the 
treatment of IRDS.  
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2.11 Research Objectives 
i. To prepare synthetic surfactant, Synsurf® with the addition of varying concentrations of 
cholesterol (Chol), tripalmitin (triPA) and palmitic acid (PA). 
ii. To examine changes in particle characteristics with the use of laser diffraction and determine 
the stability of particles within different preparations post-nebulisation, by the use of a vibrating 
mesh (membrane) nebuliser. 
iii. To determine changes in density, viscosity and surface tension of surfactant preparations under 
(i), and compare findings to commercially available natural surfactant, Curosurf® and Liposurf® 
at a similar PL concentration (20 mg/mL).  
iv. To extrapolate the results obtained and contribute to future deposition studies for the 
development of an optimal formulation and preparation (by possible extrusion) of Synsurf® 
surfactant, administered by nebulisation. 
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CHAPTER 3: Experimental Materials and Methods 
3.1 Materials  
Chemicals used and company/source are shown in Table 3.1. All chemicals used were of the highest 
analytical grade. Curosurf® (poractant alfa, porcine PS, classified as a natural surfactant) and Liposurf® 
(bovine lipid extract surfactant, classified as a natural surfactant) were analysed in the same way as 
Synsurf® preparations, with regards to density, viscosity, particle characteristic pre- and post-
nebulisation and surface tension lowering ability. Curosurf® (containing 80 mg/mL phospholipid) and 
Liposurf® (containing 27 mg/mL phospholipid) were diluted with (0.1M NaCl) to an overall 
phospholipid concentration of 20 mg/mL, thus all surfactants used in the study had a final PL 
concentration of 20 mg/mL. 
 
Table 3.1: Chemicals used in the synthesis and analyses of synthetic and natural surfactant preparations 
are indicated with the corresponding manufacturing company.  
# Chemical/Material Company/Source 
1 
1,2_Dipalmitoyl-L-α-phosphatidylcholine 
(DPPC) 
Avanti Polar Lipids (Alabaster, Alabama, 
USA) 
2 1,2-Dipalmitoyl-L-α -phosphatidylglycerol (PG) Sigma-Aldrich (St Louis, Missouri, USA) 
3 1-Hexadecanol (Cetyl alcohol) Sigma-Aldrich (St Louis, Missouri, USA) 
4 Tyloxapol - BioXtra Sigma-Aldrich (St Louis, Missouri, USA) 
6 Poly-L-lysine (Molecular weight 16 kDa) Sigma-Aldrich (St Louis, Missouri, USA) 
7 Poly-L-glutamic acid (Molecular weight 12 kDa) Sigma-Aldrich (St Louis, Missouri, USA) 
8 Cholesterol (Chol) Sigma-Aldrich (St Louis, Missouri, USA) 
9 Glyceryl Tripalmitate (Tripalmitin) (triPA) Sigma-Aldrich (St Louis, Missouri, USA) 
10 Palmitic Acid (Hexadecanoic Acid) (PA) Sigma-Aldrich (St Louis, Missouri, USA) 
11 Sterile filtered water Sigma-Aldrich (St Louis, Missouri, USA) 
12 NaCl (0.1 M solution) Sigma-Aldrich (St Louis, Missouri, USA) 
13 Chloroform (CHROMASOLV®-plus for HPLC) Sigma-Aldrich (St Louis, Missouri, USA) 
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3.2 Research Design 
3.2.1 Preparation of synthetic pulmonary surfactant Synsurf® 
Synsurf® was synthesised as described previously by, van Zyl JM, Smith J & Hawtrey A.60 Table 3.2 
show the different preparations of Synsurf® used in this study.  
Synsurf® was prepared by gently mixing DPPC, 1-Hexadecanol and PG (with the addition of Chol, 
TriPA and/or PA – see Table 3.2) in chloroform until all constituents were dissolved. The DPPC: 
Hexadecanol: PG: Additive (Chol, triPa, PA) mixture was transferred to a round-bottomed (250 mL) 
flask and kept at room temperature (23°C) for 90 min. Thereafter organic solvent (chloroform) was 
removed via rotary evaporation for 15 min at 37°C. The remainder of organic solvent was removed by 
continuous flow of N2 gas and the dried lipid mixture was stored overnight (sealed under N2). The dried 
lipid mixtures were hydrated with NaCl-solution which included a poly-L-lysine and poly-L-glutamic 
acid construct (4.35 %). After the addition of the construct and NaCl-solution , the mixture was stored 
for an additional 12 hours, under N2, for optimal hydrating of lipids. Larger multimellar vesicles were 
disrupted via ultrasonification to produce smaller unimellar vesicles. Ultrasonification was done with a 
Qsonica Q500 (Newton, Connecticut, USA) with a tip diameter of 25 mm. The amplitude was 30 µm 
and a total energy of ~ 7550 J was applied. After ultrasonification, preparations were rested overnight 
under N2 atmosphere (at 4°C). Tyloxapol was added and the mixture stirred thoroughly, followed by an 
additional resting period of 12 hours under a N2 environment at 4°C. After the final resting period 
preparations were stored in sterile vials under N2, at 4°C, ready for analysis. The final PL concentration 
was 20 mg/mL. 
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 Table 3.2: The composition of 6 different Synsurf® preparations (# 1 is Synsurf® with no additions),      
2-6 is Synsurf with the addition of PA, Chol and TriPA prepared for analyses. (*calculated on PL 
content =20 mg/mL))
Code Synsurf® samples with additions  Composition  
1 Synsurf® with no additions 20 mg/mL PL  
2 Synsurf® + Palmitic acid 20 mg/mL PL + *11 % PA  
3 Synsurf® + 2 % Cholesterol 20 mg/mL PL + *2 % Chol 
4 Synsurf®+ 2 % Cholesterol + Palmitic acid 20 mg/mL PL + *2 % Chol + *11 % PA 
5 Synsurf® + 1 % Cholesterol 20 mg/mL PL + *1 % Chol  
6 Synsurf® + Palmitic acid + Tripalmitin 20 mg/mL PL + *11% PA + *7 % triPA 
 
3.2.2 Liposome preparation and extrusion   
Extrusion is used to reduce the size and lamellarity of vesicles within lipid mixtures, thus refining target 
size of liposomes that increases stability.78 Thus including the process of extrusion during the synthesis 
of Synsurf® preparation, assists in the attainment of liposomes within the recommended size range.  
To investigate the effect of extrusion on particle characteristics and bio-activity (surface tension 
lowering ability), 10 mL of Synsurf® samples (as shown in Table 3.2) were extruded with a LiposoFast® 
LF-50 instrument at 600 psi/ 40 bar. The temperature was maintained with a water bath regulated sleeve 
at 45°C. Extruded samples were stored in sterile vials and used for analysis within one week of 
extrusion.    
3.2.3 Ageing and long-term storage of samples 
Synsurf® preparations sealed in sterile vials (under N2) were aged at 4°C, for 105 days (15 weeks), after 
which the samples were analysed for changes in bio-activity and particle characteristics. These analyses 
were included to establish a preliminary “shelf-life” of Synsurf® with additions.  
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3.2.4 Density experiments 
For the analysis of surface tension, with the DSA25, the difference in density of the surrounding phase 
(air for non-submerged pendant drop) and liquid used for drop, is required. The densities of all samples 
were determined by the use of an AccuPyc™ 1330 Pycnometer at Cape Peninsula University of 
Technology (CPUT), Chemical Engineering Laboratories. Pure water (Sigma-Aldrich®) was tested 
before each run with temperature maintained at 25.0°C ± 0.2°C and displayed a density of 0.996 ± 0.03 
g/cm3. This is in accordance with the biophysical properties of pure water by Sigma-Aldrich® of 0.9970 
g/cm3 at 25°C. Analyses were conducted at 25°C to determine density for each Synsurf®, Curosurf® and 
Liposurf® surfactant preparation, pre- and post-nebulisation (n=5). 
3.2.5 Liquid surface tension experiments 
A drop shape analysis system by KRÜSS (DSA25, KRÜSS Inc., Germany) was used to determine the 
semi-dynamic surface tension changes over time of prepared surfactant samples. KRÜSS DSA25 
instruments (Figure 3.1) located at the Department of Chemistry and Polymer Science laboratories at 
Stellenbosch University, Nutec Digital Ink (Pty) Ltd, Ottery and University of Western Cape, Chemistry 
Department were used (depending on the availability). The instruments (DSA25) were calibrated with 
distilled water with a surface tension value of 72 mN/m (as recommended by operational/software 
manual). After the addition of density values (as determined in 3.3.4)  to the software data base, samples 
were suspended from a steel needle as shown in Figure 3.1 in the upper left corner.79 Surface tension 
changes were recorded over 900 seconds (15 min). All analyses were completed in triplicate. Decrease 
in surface tension was calculated by means of a normalization ratio, determined by the initial reading 
at time point 0 (for each sample), divided by the decreasing values recorded at 15 second intervals.   
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Figure 3.1: Shows the KRÜSS DSA25 instrument, situated at Department of Chemistry and Polymer 
Science, Stellenbosch University. The enlarged image in the left-hand corner shows the drop as 
suspended from the pendent drop needle (sample = Synsurf® with no addition [PL] = 20 mg/mL).  
3.2.6 Viscosity experiments 
The viscosity of samples could be semi-quantified with the use of Leja® 4-Chamber slides with defined 
dimensions (depth 20 μm, length 21 mm, width 6 mm). The viscosity of a specific fluid indicates the 
resistance against natural flow. Thus the theoretical assumption is made that a linear relationship exists 
between filling time of the slide and the viscosity of the specific liquid.80 Leja® 4-Chamber precision 
slides were purchased from Delfran (Pty) Ltd. Slides were placed on a level surface and filling times 
were recorded with a stopwatch. Filling times were logged between applications of the sample at the 
inlet of the slide until the tapered outlet of the slide was reached. Pure water was used as a control, with 
the temperature maintained close to 25°C (0.912 ± 0.02 cP). All analyses were completed in triplicate. 
Conversion tables as provided by the Leja® official website were used to convert the filling times to 
centipoise (cP).81 
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3.2.7 Surfactant preparation nebulisation experiments 
Synsurf® preparations (aged and extruded samples included), Curosurf® and Liposurf® were nebulised 
with the use of the Aeroneb®Pro vibrating mesh nebuliser. An experimental set-up for aerosol delivery 
and capturing of generated surfactant particles was constructed, which consisted of the Aeroneb®Pro 
nebuliser, connected to a glass dilution container and a medical oxygen line that propelled the aerosol 
into the dilution container (Figure 3.2). A flow regulator was fitted to the medical oxygen line to 
maintain the oxygen flow rates at 2.0 L/min. All samples were nebulised for 10 min and liquid collection 
from the dilution container was sealed in glass vials, and used for analyses thereafter.  
 
Figure 3.2: Experimental set-up for collection of nebulised samples (Synsurf® preparations, Curosurf®, 
and Liposurf®). The image shows the Aeroneb®Pro reservoir connected to the dilution container filled 
with thick nebulised mist generated with Synsurf®. 
3.2.8 Particle characterisation  
Z-Average particle size: 
Particles within samples which included Synsurf®, Curosurf® and Liposurf® preparations were analysed 
with the use of a Malvern Zetasizer® Nano-S ZEN 1600 stationed at the Chemistry and Polymer Science 
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laboratories at Stellenbosch University. The z-average particle size, is a hydrodynamic parameter, and 
can only be analysed for molecules in a suspension with dynamic light scattering (DLS). Z-average size 
is typically larger than “dry-particle” analyses (this can include SEM and TEM), and particles size is 
dependent on the concentration of the solution (this includes particle structure) and the ion contents.82  
NaCl-solution (0.1 M) was prepared with sterile water and filtered with a 0.22 µm nylon filter attached 
to a standard sterile 10 ml syringe. Nebulised samples collected from the dilution container generated 
during nebulisation as well as non-nebulised samples were diluted 1:2 with filtered NaCl-solution and 
placed in a standard polystyrene cuvette (10 x 10 x 45 mm). The cuvette was filled to 1/3 of its total 
capacity. Z-average particle size (expressed as diameter in nanometres (d.nm)) was recorded as 
calculated by the software. Results included (13 x 3) particle analyses per run done in triplicate at 25°C. 
The poly dispersion index (Pdi) (ranging from 0 to 1) is a size distribution parameter and values closer 
to 0 indicate monomodal (near spherical shape) and/or monodisperse (narrow width of distribution) 
particles. A Pdi ranging from 0.7 to 1 will be rejected as the sample is not suitable for DLS analyses. 
For the optimal operation of the software (calculations), the Pdi range from 0.08 to 0.7.83  
Visualisation of particles by scanning electron microscopy (SEM): 
Particles within nebulised and non-nebulised samples of Synsurf®, Curosurf® and Liposurf® were 
visualised with the use of ZEISS EVO MA15VP, scanning electron microscope (SEM) located at the 
Central Analytical Facility of Stellenbosch University. Microparticles were prepared by placing a 
droplet (of the liquid surfactant) on a “stub” (sample holder) covered with a 1 cm x 1 cm piece of double 
sided carbon tape. After drying in an enclosed glass dome, (for a period of 24 hours in atmospheric air 
at room temperature), samples where coated with a thin layer of gold to ensure conductivity required 
for accurate measurements and images generated were saved on the instrument software. 
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3.3 Overview of research design 
The flowchart below provides an overview of the research design and includes: synthesis, preparation 
and analyses of synthetic and natural surfactants.  
 
Figure 3.3: Flowchart of analytical methods used in the study. Starting with the synthesis and 
preparations of surfactants (shown at the top of the chart), followed by nebulisation and analyses. 
3.4 Data/statistical analysis 
Data analyses were conducted by the Centre of Evidence-Based Health Care, Stellenbosch University. 
A non-parametric, Kruskal–Wallis test was used and data are expressed as mean ± standard deviation, 
p25, median (p50) and p75. Additionally, all particle size data (nm in diameter) falling within the size 
requirements are investigated based on mean ± CI (95%).  The confidence interval (CI) of 95% was 
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calculated based on the mean and significant difference was accepted at p-values of < 0.05.  Surface 
tension decrease (DSA25 experiments) was re-calculated to give a normalisation ratio (initialising at 
100% at time point 15 seconds – based on the initial reading), and preparation’s ability to decrease 
surface tension, was compared by utilising a rank correlation test (Spearman's rank correlation). This 
method is used frequently84 as no assumptions are made about the underlying density parameters. 
Analyses included all data collected over 15 min at 15 second intervals (n = 3). However, for simplicity 
only time points (15, 150, 300, 450, 600, 750, 900 seconds) are indicated on graphs (See Results 4.4). 
Spearman's rank correlation coefficient (rho), with a value of less than 0.4 indicate a non-linear decrease 
in surface tension and two variables were considered to show significant correlation at p-values < 0.05.  
3.5 Ethics 
Ethics approval by the Health Research Ethics Committee 2 (HREC 2) of Tygerberg Campus, 
Stellenbosch University for this project was granted from 01 June 2015 to 01 June 2016 under the 
reference code: S15/04/088. Re-application with the submission of a progress report in 2016 was 
successful, and extension was granted from 09 March 2016 to 08 March 2017 under the reference code 
stated above.   
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CHAPTER 4: Results 
4.1 Density  
Density (ρ) of liquid preparations, which included Synsurf® (Syn), Curosurf® and Liposurf® were 
evaluated pre- and post-nebulisation, Table 4.1 and Table 4.2.  
4.1.1 Density analysis of surfactants pre-nebulisation  
Synsurf® preparations exhibited an array of densities ranging from 1.106 g/cm3 to 1.235 g/cm3 (Table 
4.1).  Statistical comparison indicated that the density of Synsurf® 5 (Chol [1 %]) is significantly higher 
than that of Synsurf® 1 (*p <0.05), Syn 2 (**p <0.001) and lower than, Syn 6 (*p < 0.05). In addition, 
the density of Synsurf® 2 in comparison to Syn 3 is significantly lower (p <0.05). Synsurf® 4 (PA and 
Chol [2 %]) indicated no considerable differences in density in comparison to the other preparations 
analysed. This also includes the densities of the natural surfactants, Curosurf® and Liposurf®. 
4.1.2 Density analysis of surfactants post-nebulisation 
A comparison of surfactant samples pre- and post-nebulisation showed a significant decrease in density 
in most preparations post-nebulisation. This included Synsurf® 4, 6 and Liposurf® as indicated in blue 
in Table 4.2.  However, Synsurf® 3, 5 and Curosurf® showed an increase in density post-nebulisation 
as marked in yellow in Table 4.2. Statistical analysis (Wilcoxon signed rank test) indicated that only 
Synsurf® 1 and 2 displayed no differences when nebulised, while the densities of all other surfactant 
preparations were significantly different post-nebulisation (*p < 0.05), with either an increase or 
decrease. 
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Table 4.1: The mean densities (g/cm3) of Synsurf® preparations (1 to 6), Curosurf® and Liposurf® pre- 
nebulisation are expressed in bold, with temperature maintained at 25°C. Additionally, standard 
deviation (± SD) and interquartile range (IQR), which includes p25, median and p75, are indicated. 
(*:p>0.05 vs Synsurf® 5; **:p>0.001 vs Synsurf® 5; ⁺:p>0.05 vs Synsurf® 2) 
 
# Sample Name: 
PRE-NEBULISATION 
Mean 
density 
(g/cm3) 
± SD  
IQR 
p25 Median p75 
1 Synsurf® 1.128* ±0.002 1.126 1.126 1.129 
2 Synsurf® with palmitic acid (PA) [11 %] 1.106** ±0.003 1.106 1.107 1.108 
3 Synsurf® with cholesterol (Chol) [2 %] 1.123⁺ ±0.004 1.121 1.125 1.126 
4 
Synsurf® with palmitic acid (PA) [11 %] + 
cholesterol (Chol) [2 %] 
1.148 ±0.002 1.145 1.149 1.149 
5 Synsurf® with cholesterol (Chol) [1 %] 1.187 ±0.012 1.184 1.187 1.193 
6 
Synsurf® with palmitic acid (PA) [11 %] + 
tripalmitin (triPA) [7 %] 
1.235* ±0.011 1.230 1.239 1.244 
OTHER SURFACTANTS: PRE-NEBULISATION 
C Curosurf® (Diluted = PL [20 mg/mL]) 1.151 ±0.008 1.143 1.151 1.157 
L Liposurf® (Diluted = PL [20 mg/mL]) 1.161 ±0.006 1.164 1.164 1.165 
 
Table 4.2: The mean densities (g/cm3) of Synsurf® preparations (1 to 6), Curosurf® and Liposurf® post- 
nebulisation are expressed in bold, with temperature maintained at 25°C. Additionally, standard 
deviation (± SD) and interquartile range (IQR), which includes p25, median and p75, are indicated. 
Significant changes (*: p<0.05 vs pre-nebulisation) in density post-nebulisation are marked in              
blue = decreased and yellow = increased.   
# Sample Name: 
POST-NEBULISATION 
Mean 
density 
(g/cm3) 
±SD 
IQR 
p25 Median p75 
1 Synsurf® 1.124 ±0.004 1.123 1.123 1.124 
2 Synsurf® with palmitic acid (PA) [11 %] 1.110 ±0.004 1.109 1.110 1.112 
3 Synsurf® with cholesterol (Chol) [2 %] 1.151* ±0.003 1.150 1.151 1.151 
4 
Synsurf® with palmitic acid (PA) [11 %] + 
cholesterol (Chol) [2 %] 
1.108* ±0.004 1.106 1.110 1.111 
5 Synsurf® with cholesterol (Chol) [1 %] 1.234* ±0.001 1.227 1.238 1.243 
6 
Synsurf® with palmitic acid (PA) [11 %] + 
tripalmitin (triPA) [7 %] 
1.082* ±0.012 1.082 1.238 1.087 
OTHER SURFACTANTS: POST-NEBULISATION 
C Curosurf® (Diluted = PL [20 mg/mL]) 1.198* ±0.001 1.188 1.196 1.207 
L Liposurf® (Diluted = PL [20 mg/mL]) 1.153* ±0.008 1.151 1.152 1.154 
Stellenbosch University  https://scholar.sun.ac.za
 46 
 
4.1.3 Comparison of Synsurf®, Curosurf® and Liposurf® pre- and post-nebulisation  
Synsurf® 1 (original formulation) showed no change in density after nebulisation (Figure 4.1). On the 
other hand, Curosurf® displayed an increase in density (± 3.9 %) post- nebulisation, while Liposurf® 
showed a decrease (± 0.7 %). Both changes were found to be significant as indicated in the Figure 4.1  
 
Figure 4.1: Mean density (g/cm3) of Synsurf®, Curosurf® and Liposurf®, pre- and post-nebulisation at 
25°C with PL [20 mg/mL]. * p = 0.0422. ** p = 0.0431 
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4.2 Viscosity 
Results of viscosity determination of Synsurf® preparations pre- and post-nebulisation (with and 
without extrusion through a 5 µm and 12 µm filter), Curosurf® and Liposurf® are shown in Table 4.3, 
4.4 and 4.5.  
4.2.1 Viscosity of Synsurf® samples pre-nebulisation (with and without extrusion)  
Synsurf® preparations showed varying viscosities ranging from 6.772 ± 0.006 cP to 26.080 ± 0.003 cP 
(Table 4.3). All Synsurf® formulations showed significant differences with additions, with               
Synsurf® 2-5 showing higher viscosity values and Synsurf® 6 with palmitic acid and tripalmitin had a 
lower viscosity.  However, statistical comparison of non-extruded in comparison to extruded samples 
(with either a 5 µm or 12 µm filters) showed no significant inter-formulation differences. Synsurf® 4 
(PA and chol [2 %]) had the highest viscosity, followed by Synsurf® 3 (chol [2 %]).  In contrast to this, 
Synsurf® 5 (1 % chol) had a lower viscosity of 9.008 ± 0.003 cP, more similar to that of Synsurf® 1. 
The lowest viscosity was found for Synsurf® 6. However, this formulation was unable to extrude with 
a 5 µm pore filter due to clogging and thus no data is available, as indicated in the Tables.    
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Table 4.3: Viscosity (cP) ± SD of Synsurf® preparations with additional extrusion steps (5 µm or 12 µm 
filter), pre-nebulisation. (*:p<0.05 vs Synsurf® 1) 
PRE-NEBULISATION 
# Sample Name: 
Non-Extruded Extruded 5 µm Extruded 12 µm 
Viscosity (cP) mean ± SD 
1 Synsurf® 7.789 ± 0.092 7.595 ± 0.103 7.620 ± 0.109 
2 
Synsurf® with palmitic acid (PA) 
[11 %] 
10.608 ± 0.085* 10.426 ± 0.076 10.553 ± 0.111 
3 
Synsurf® with cholesterol (Chol)     
[2 %] 
21.081 ± 0.169* 20.752 ± 0.158 21.080 ± 0.002 
4 
Synsurf® with palmitic acid (PA) 
[11 %] and cholesterol (Chol) [2 %] 
26.080 ± 0.207* 25.62 ± 0.157 25.736 ± 0.058 
5 
Synsurf® with cholesterol (Chol)    
[1 %] 
9.008 ± 0.052* 8.966 ± 0.086 8.890 ± 0.358 
6 
Synsurf® with palmitic acid (PA) 
[11 %] and tripalmitin (triPA)[7 %] 
6.772 ± 0.204* *unable extrude 6.399 ± 0.020 
 
4.2.2 Viscosity of Synsurf® samples post-nebulisation (with and without extrusion) 
Nebulised Synsurf® preparations (2-6) showed a statistical significant inter-formulation decrease in 
viscosity (Table 4.4) post-nebulisation ranging from 4.733 ± 0.005 cP to 9.351 ± 0.007 cP (*p < 0.05). 
Similar to results in Table 4.3, inclusion of an extrusion step in the synthesis, did not result in a statistical 
significant difference in viscosity post-nebulisation. Synsurf® 6 (addition of PA and triPA) was again 
unable to extrude through a 5 µm pore filter due to clogging. However, with a 12 µm pore filter 
extrusion was possible with no change in viscosity post-nebulisation. Compared to non-nebulised 
preparations, Synsurf® formulations showed a significant decrease in viscosity post-nebulisation 
however, Synsurf® 1 showed no changes in viscosity after nebulisation.   
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Table 4.4: Viscosity (cP) of nebulised preparations, collected from the dilution container. Viscosity is 
shown for non-extruded and extruded samples post-nebulisation ± SD. (*:p<0.05 vs pre-nebulisation)   
POST-NEBULISATION 
# Sample Name: 
Non-Extruded Extruded 5 µm Extruded 12 µm 
Viscosity (cP) mean ± SD 
1 Synsurf® 7.514 ± 0.011 7.375 ± 0.010 7.26 ± 0.094 
2 
Synsurf® with of palmitic acid 
(PA) [11%] 
8.868 ± 0.178* 8.604 ± 0.010 8.468 ± 0.028 
3 
Synsurf® with cholesterol (Chol) 
[2%] 
7.507 ± 0.165* 7.487 ± 0.200 7.149 ± 0.187 
4 
Synsurf® with palmitic acid (PA) 
[11%] and cholesterol (Chol) [2%] 
9.351 ± 0.182* 9.280 ± 0.193 9.998 ± 0.204 
5 
Synsurf® with cholesterol (Chol) 
[1%] 
5.378 ± 0.114* 5.289 ± 0.054 4.973 ± 0.067 
6 
Synsurf® with palmitic acid (PA) 
[11%] and tripalmitin (triPA) [7%] 
4.733 ± 0.184* *unable extrude 4.525 ± 0.091 
 
4.2.3 Viscosity analysis of natural surfactants, Curosurf® and Liposurf® pre- and post-nebulisation 
Analyses of commercially available natural surfactants displayed lower viscosities at the same PL 
concentration as Synsurf® preparations. No statistical significant differences were found between 
Curosurf® and Liposurf®, pre- and post-nebulisation, respectively. 
Table 4.5: Viscosity cP ± SD of Curosurf® and Liposurf® pre- and post-nebulisation. Both surfactants 
were diluted to a phospholipid concertation of [20 mg/mL].  
CUROSURF® AND LIPOSURF® 
# Sample Name: 
PRE-NEBULISATION POST-NEBULISATION 
Viscosity (cP) mean ± SD 
C Curosurf®  3.012 ± 0.013 2.834 ± 0.007 
L Liposurf®  4.064 ± 0.020 3.084 ± 0.018 
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4.3 Particle size determination 
The z-average particle size ± SD of samples tested pre- and post-nebulisation, are shown in Table 4.6. 
Particle dimensions are expressed as diameter in nanometres (d.nm). As mentioned previously, the 
optimal particle size post-nebulisation should ideally range from 1000 nm to 3000 nm in diameter.   
4.3.1 Comparison of Synsurf® preparations at day of synthesis (day 0) 
Particle size analyses of Synsurf® preparations, immediately after synthesis indicated an array of 
particle sizes amongst the different formulations. Synsurf® 2 (PA) and 4 (PA plus Chol [2 %]) showed 
large particles approximately 6339 d.nm and 7908 d.nm in diameter. However, Synsurf® 6 (PA and 
triPA) contained smaller particles (3150 d.nm). Synsurf® 1 and 5 had smaller particles, in comparison 
to other formulations, pre-nebulisation (2336 d. nm and 2911 d.nm) and  comparison of Synsurf® 3 and 
5 (with cholesterol [2 %] and [1 %]) respectively showed similar particle diameter.  
4.3.2 Comparison of Synsurf® preparations pre- and post-nebulisation  
Nebulisation of Synsurf® preparations showed a considerable decrease in the diameter of particles 
collected after aerosolisation. Post-nebulisation, particles ranged from ± 351 d.nm to ± 779 d.nm (Table 
4.6). In comparison to other Synsurf® formulations that showed a decrease ~ 80% – 90%, Synsurf® 6 
had a lower decrease in particles diameter of ~ 44%. Statistical analysis indicated a 95% CI that the 
particles generated by nebulisation of Synsurf® 6 fell within the desired size range. (indicated in green 
in Table 4.6) 
4.3.3 Changes in particle size with ageing of Synsurf® preparations 
Although not significant, Synsurf® preparations showed slight changes in particles diameter pre- and 
post-nebulisation on day 105 in comparison to day 0.  
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4.3.4 Changes in particle size of extruded Synsurf® preparations post-nebulisation 
The addition of extrusion as synthesis step changed the average particles diameter observed in almost 
all Synsurf® preparations. An overall increase in post-nebulisation particle diameters is observed for 
extruded preparations, in comparison to non-extruded formulations as shown in Figure 4.2.  
Synsurf® 1 - 5 (extruded with 5 µm or 12 µm filter) showed an increase in post-nebulisation particles in 
comparison to non-extruded nebulised preparations. However, Synsurf® 6 was unable to be extruded 
with a 5 µm filter (0 in Figure 4.2) and showed a large decrease in particle size when extruded with a 
12 µm filter and nebulised. 
Figure 4.2: Average particle size (d.nm) of Synsurf® preparations 1 to 6, non-extruded and extruded 
with a 5 µm and 12 µm filter, post-nebulisation. Bars = SEM 
 
Synsurf 1 Neb Synsurf 2 Neb Synsurf 3 Neb Synsurf 4 Neb Synsurf 5 Neb Synsurf 6 Neb
Not Extruded 533.6 778.5 414.8 524 351.2 1779.7
Extruded 5 μm filter 1033.33 1751.89 1239 917.79 666.96 0
Extruded 12 μm filter 1960 1324.37 1147 1148.67 1226.89 304.04
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4.3.5 Particle size analyses of Curosurf® and Liposurf® 
Curosurf® and Liposurf® showed average particles diameters comparable (but statistically different) to 
Synsurf® 1, 3 and 5 (see Table 4.6) post-nebulisation. Curosurf® and Liposurf® generated particles 
smaller than the suggested (optimal) range for nebulised aerosols.  
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Table 4.6: Z-Average particle sizes of preparations pre- and post-nebulisation. The average particle size (± SD) is expressed in diameter in nanometres (d.nm) 
for Synsurf® preparations (ageing 105 days and extrusion with a 5 μm or 12 μm filter). Curosurf® and Liposurf® shown pre- and post-nebulisation.  
 
Batch 
Sample 
Name 
# 1 Synsurf®  
# 2 Synsurf®      
(PA) 
# 3 Synsurf®        
(Chol 2 %) 
# 4 Synsurf®         
(PA and Chol 2 %) 
# 5 Synsurf®      
(Chol 1 %) 
# 6 Synsurf®         
(PA and triPA) 
Nebulisation 
Status: 
Pre-Neb  Post-Neb Pre-Neb Post-Neb Pre-Neb Post-Neb Pre-Neb Post-Neb Pre-Neb Post-Neb Pre-Neb Post-Neb 
Day 0 
Z
-a
v
er
a
g
e 
p
a
rt
ic
le
 s
iz
e 
(d
ia
m
et
er
 i
n
 n
m
) 
±
 S
D
 
2336  
(±69) 
534  
(±7) 
6339 
(±42) 
779 
(±26) 
3420 
(±49) 
415 
(±30) 
7908 
(±63) 
524 
(±12) 
2911 
(±24) 
351 
(±23) 
3150 
(±64) 
1780 
(±53) 
Day 105 
2758 
(±52) 
479 
(±36) 
6005 
(±69) 
789 
(±43) 
3801 
(±61) 
423 
(±46) 
7911 
(±55) 
500   
(±8) 
2898 
(±22) 
394   
(±9) 
2911 
(±53) 
1789 
(±50) 
Extruded 
with a        
5 µm filter 
3247 
(±43) 
1033 
(±54) 
4887 
(±46) 
1752 
(±29) 
4878 
(±49) 
1239 
(±30) 
4345 
(±28) 
918 
(±12) 
1941 
(±22) 
667 
(±15) 
no 
reading 
no 
reading 
Extruded 
with a      
12 µm filter 
4296 
(±69) 
1960 
(±10) 
8047 
(±20) 
1324 
(±26) 
6554 
(±26) 
1147 
(±20) 
8554 
(±25) 
1149 
(±11) 
3823 
(±36) 
1227 
(±23) 
2176 
(±83) 
304   
(±5) 
Curosurf® 
and 
Liposurf® 
Curosurf® Liposurf®         
2083 
(±55) 
427 
(±17) 
3260 
(±121) 
403  
(±7) 
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4.3.6 Scanning electron microscopy (SEM) 
SEM visualisation was performed for all Synsurf® preparations, Curosurf® and Liposurf® pre – and post 
nebulisation. However, due to the topographical nature of SEM, not all images generated were of 
excellent quality and/or provided structural information about particles/liposomes, thus only images 
that complied are included. In all the Figures (4.3 to 4.13) dehydration and collapse of liposomes can 
be seen. A single dehydrated liposome (Synsurf® 1) is shown in Figure 4.3. The elevation surrounding 
the liposome, giving a “doughnut-like” appearance is likely due to rapid dehydration deployed in the 
fixing process. Particle diameter (z-average) determined by DLS for Synsurf® 1 is ± 2336 d.nm (2.3 
d.µm), as shown in Table 4.6 and Figure 4.3 show the liposome is similar in size as determined by the 
SEM. Although SEM provided topographical imaging of surfactant preparations, some edges of the 
deflated liposomes (Synsurf® 1), indicated in Figure 4.4 by black arrows could be observed, whilst 
others were tucked under the surface, thus not showing the complete structure. Dense patches of 
collapsed liposomes are illustrated in Figure 4.5 and 4.8 (Synsurf® 3 and 6 pre-nebulisation), similar to 
the average particle size (± 3.4 d.µm and ± 3.6 d.µm) as determined by DLS analyses. However, some 
liposomes are embedded and the full structure is not visible. Arrangement of liposomes in Synsurf® 4 
pre-nebulisation is shown in Figure 4.6. Liposomes presented in a “beads on a string” like structure, 
indicated with arrows. SEM imaging of Synsurf® 5 (Chol [1 %]) pre-nebulisation showed very dense 
packed spherical liposomes, with a topographic covering (Figure 4.7). Although the liposome structures 
are covered, an estimate particle size of ± 2 – 3 d.µm is seen. Nebulisation generated particles much 
smaller than those found in solutions pre-nebulisation (Table 4.6). Figure 4.9 and 4.10 show Curosurf® 
post- nebulisation. The measured liposome is indicated in a dialog box in Figure 4.9, and show a rough 
diameter of ± 600 d.nm. Liposurf® post-nebulisation shows a dense, almost cluster-like, packing of 
liposomes (Figure 4.11). Synsurf® 5 (Chol [1%]), that had the smallest particles post-nebulisation 
(Table 4.6), Figure 4.12 illustrates a rough surface with numerous liposomes, presents as white specs 
spread evenly throughout the image. Synsurf® 6 maintained particle size within the desired range post-
nebulisation (Table 4.6), and is presented in Figure 4.13.  
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Figure 4.3: A SEM image of     
Synsurf® 1 pre-nebulisation. 
Parameters of the recorded image are 
shown at the bottom. Arrows indicate 
the edges of a dehydrated liposome. 
Scale bar = 2 µm 
 
 
Figure 4.4: A SEM image of              
Synsurf® 1 pre-nebulisation. Visible 
deflated liposome edges are indicated 
with black arrows and the inner 
diameter of another liposome is shown 
in the black dialog box (1.426 µm). 
Parameters of the recorded image are 
shown at the bottom. Scale bar = 2 µm 
 
Figure 4.5: A SEM image of      
Synsurf® 3 pre-nebulisation. Semi-
spherical liposome structures are 
shown on the surface of the image.  
Parameters of the recorded image are 
shown at the bottom. Scale bar = 2 µm 
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Figure 4.6: A SEM image of           
Synsurf® 4 pre-nebulisation. Black 
arrows indicate “beads on a string” 
like structures formed by liposomes. 
Parameters of the image are indicated 
at the bottom, including a bar scale = 
10 µm.    
 
 
Figure 4.7: A SEM image of         
Synsurf® 5 pre-nebulisation showing 
dense compaction of similar shaped 
particles. Parameters of the recorded 
image are shown at the bottom. Scale 
bar = 2 µm 
 
 
Figure 4.8: A SEM image of  
Synsurf® 6 pre-nebulisation. 
Parameters of the image are indicated 
at the bottom, including a bar scale = 
2 µm.     
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Figure 4.9: A SEM image of Curosurf® 
post-nebulisation. White measurement 
circle surrounding liposome = 598.5 
d.nm. Parameters of the recorded 
image are shown at the bottom. Scale 
bar = 2 µm 
 
 
Figure 4.10: A SEM image of 
Curosurf® post-nebulisation. 
Parameters of the recorded image are 
shown at the bottom. Scale bar = 1 µm 
 
 
 
 
 
Figure 4.11: A SEM image of 
Liposurf® post-nebulisation. 
Parameters of the recorded image are 
shown at the bottom. Scale bar = 1 µm 
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Figure 4.12: A SEM image of 
Synsurf® 5 post-nebulisation. 
Parameters of the recorded image are 
shown at the bottom. Scale bar = 10 
µm 
 
 
 
 
Figure 4.13: A SEM image of 
Synsurf® 6 post-nebulisation. 
Parameters of the recorded image are 
shown at the bottom. Scale bar = 2 µm 
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4.4 Interfacial surface tension reduction analyses 
The following sections show the results of interfacial surface tension analyses of all surfactants pre- 
and post-nebulisation. Surface tension changes were analysed by pendant drop method for 900 seconds        
(as described in Materials and Methods 3.2.5). To compare changes in nebulisation status pre- and post-
nebulisation, aging and addition of extrusion in synthesis of Synsurf® samples, results recorded in 
m/Nm, were converted to a normalisation ratio (%) to depict the reduction of surface tension of 
preparations.   
4.4.1 Interfacial surface tension reduction of surfactant samples pre-nebulisation 
The reduction in surface tension (%) over 900 seconds of Synsurf® 1 - 6 is shown in Figure 4.14. A 
decrease in surface tension is observed for all Synsurf® preparations. However, Synsurf® 5 and 6 
showed an overall more rapid decrease in surface tension over the total observation period (± 26 % and 
± 23 %, respectively). Comparative analysis showed that the decrease in surface tension of             
Synsurf® 1 - 4 was significantly different to that of Synsurf® 5 and 6. Moreover, no statistical difference 
was found between Synsurf® 5 and 6, pre-nebulisation. 
Surface tension reduction of Synsurf® 1, Curosurf® and Liposurf® showed vast differences, although a 
decrease in surface tension was presented by all surfactants, Curosurf® and Liposurf® showed an overall 
greater decrease in surface tension within the first 150 seconds, that was significantly different to 
Synsurf® preparation 1. After a plateau of about 150 seconds Liposurf® decreased surface tension further 
in comparison to both Curosurf® and Synsurf® 1 (Figure 4.15).  
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Figure 4.14: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre-
nebulisation Synsurf® preparations over time. (*: p<0.05 vs Synsurf® 1-4). 
Figure 4.15: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre-
nebulisation Synsurf® 1, Curosurf® and Liposurf® preparations over time. (*: p<0.05 vs Synsurf® 1 pre-
nebulisation) 
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4.4.2 Interfacial surface tension reduction of surfactants pre- and post-nebulisation 
Changes in interfacial surface tension reduction pre- and post-nebulisation of Synsurf®, Curosurf® and 
Liposurf® preparations are shown in Figures 4.16 to 4.24. Synsurf® 2, 3, 4 and 5 showed statistical 
significant differences with regards to reduction of surface tension, with post-nebulisation samples over 
900 seconds (see Figures 4.17 to 4.20). However, Synsurf® 1 and 6 showed no significant changes in 
interfacial surface tension reduction pre- and post-nebulisation over the 900 second period (Figures 4.16 
and 4.21). Similar, to Synsurf® preparations 2 - 5, Curosurf® and Liposurf® showed statistical significant 
change in interfacial surface tension reduction post-nebulisation, over the observation period. (see 
Figures 4.22 and 4.23). Although Synsurf® preparations 2, 3, 4 and 5 showed a significant decline in 
surface tension post-nebulisation, the changes observed were less profound in comparison to Curosurf® 
and Liposurf®.  
Synsurf® preparation 1: 
Synsurf® 1 showed no statistical significant changes in surface tension reduction ability post- 
nebulisation over the observation period.  
Figure 4.16: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 1 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation.
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Synsurf® preparation 2: 
Synsurf® 2 showed statistical significant differences in reduction of surface tension over the observation 
period.  
Figure 4.17: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 2 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation. (*: p<0.05 vs Synsurf® 2 pre-nebulised) 
Synsurf® preparation 3: 
Synsurf® 3 showed statistical significant differences in reduction of surface tension over the observation 
period.  
 Figure 4.18: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 3 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation. (*: p<0.05 vs Synsurf® 3 pre-nebulised) 
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Synsurf® preparation 4: 
Synsurf® 4 showed statistical significant differences in reduction of surface tension over the observation 
period.   
Figure 4.19: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 4 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation. (*: p<0.05 vs Synsurf® 4 pre-nebulised) 
Synsurf® prepation 5: 
Synsurf 5 showed statistical significant differences in reduction of surface tension over the observation 
period.  
Figure 4.20: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 5 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation. (*: p<0.05 vs Synsurf® 5 pre-nebulised) 
Stellenbosch University  https://scholar.sun.ac.za
 64 
 
Synsurf® preparation 6:  
Synsurf® 6 showed no statistical significant changes in surface tension reduction ability post-
nebulisation over the observation period.  
Figure 4.21: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 6 preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation.   
Curosurf®: 
Curosurf® showed statistical significant differences in reduction of surface tension over the observation 
period.  
Figure 4.22: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Curosurf® preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation.(*: p<0.05 vs Curosurf®  pre-nebulised)   
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Liposurf®: 
Liposurf® showed statistical significant differences in reduction of surface tension over the observation 
period.  
  
Figure 4.23: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Liposurf® preparation over time. The abbreviation Neb signifies the nebulisation 
status as post-nebulisation.(*: p<0.05 vs Liposurf®  pre-nebulised)    
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 66 
 
4.4.3 Comparison of Synsurf® 1, Curosurf® and Liposurf® post-nebulisation 
Figure 4.24 shows that nebulised samples of Synsurf® 1, Curosurf® and Liposurf® had an overall similar 
trend in the reduction of surface tension. Synsurf® 1 Neb is signified in blue, Curosurf® Neb in orange 
and Liposurf® in grey. However, Liposurf® showed a significant further reduction in surface tension 
between 600 – 900 seconds.  
Figure 4.24: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of post-
nebulisation Synsurf® 1, Curosurf® and Liposurf® preparation over time. The abbreviation Neb signifies 
the nebulisation status as post-nebulisation. (*: p<0.05 vs Synsurf® 1 post-nebulisation) 
4.4.4 Interfacial surface tension reduction of Synsurf® samples with ageing 
Changes in interfacial surface tension reduction (%) was determined for Synsurf® preparations on the 
day of synthesis (marked as day 0) and after ageing (at 105 days). The results are shown in Figure 4.25 
to 4.30. Synsurf® preparations 1, 2, 5 and 6 showed no significant changes in surface tension reduction 
over the 105 days with samples pre- and post-nebulisation. However, Synsurf® preparation 3 showed a 
decrease in surface tension lowering ability after 105 days when nebulised (in comparison to un-aged 
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sample). Indicated in yellow in Figure 4.27, a slight diminishing in surface tension reduction was 
observed between 600 to 900 seconds. Synsurf® 4 showed a slight increase in interfacial surface tension 
reduction post-nebulisation with aging as shown in Figure 4.28.  
Synsurf® preparation 1: 
 
Figure 4.25: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 1 preparation at day 0 and 105, over time. Neb = post- nebulisation.  
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Synsurf® preparation 2: 
Figure 4.26: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 2 preparation at day 0 and 105, over time. Neb = post- nebulisation. 
Synsurf® preparation 3: 
Figure 4.27: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 3 preparation at day 0 and 105, over time. Comparison showed statistical 
differences between nebulised preparation at day 0 and 105 (shown in orange and yellow) between 600 
– 900 seconds. Neb = post- nebulisation. (*: p<0.05 vs Synsurf® 3 post-nebulised day 0) 
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Synsurf® preparation 4: 
Figure 4.28: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 4 preparation at day 0 and 105, over time. Comparison showed statistical 
differences (p < 0.05) between nebulised preparation at day 0 and 105 (shown in orange and yellow). 
Neb = post- nebulisation. (*: p<0.05 vs Synsurf® 4 post-nebulised day 0) 
Synsurf® preparation 5: 
 
Figure 4.29: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 5 preparation at day 0 and 105, over time. Neb = post- nebulisation. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 70 
 
Synsurf preparation 6: 
Figure 4.30: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- and 
post-nebulisation Synsurf® 6 preparation at day 0 and 105, over time. Neb = post- nebulisation. 
 
4.4.5 Interfacial surface tension reduction of Synsurf® samples extruded in synthesis 
Comparison of Synsurf® samples prepared with or without an additional extrusion steps, indicated no 
changes in surface tension reduction for all Synsurf® preparations (1 – 6) pre- and post-nebulisation. 
Reduction in surface tension of Synsurf® 1 (extruded) pre-nebulisation (Figure 4.31) and post-
nebulisation (Figure 4.32) is shown. As extrusion did not significantly change the surface tension 
reduction ability of Synsurf® preparations (pre- and post-nebulisation), extruded and non-extruded 
preparations showed similar results.  
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Pre-nebulisation: 
Figure 4.31: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of pre- 
nebulisation Synsurf® 1 (extruded by 5 µm and 12 µm filter), over time.  
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Post-nebulisation:  
Figure 4.32: Interfacial surface tension reduction (expressed in % and SEM bar indicated) of post- 
nebulisation Synsurf® 1, extruded by 5 µm and 12 µm filter, over time. Neb = post- nebulisation.  
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CHAPTER 5: Discussion 
Surfactant replacement therapy (SRT) is an established treatment for infant respiratory distress 
syndrome (IRDS); however, care of extremely premature infants less than 26 weeks, have encouraged 
new methods to SRT administration in combination with the clinical focus of reducing and/or avoiding 
mechanical ventilation.85 Older human and animal studies investigating nebulised SRT showed non-
beneficial results53 however, recent studies indicated the safety and feasibility of SRT by 
aerosolisation.56,74 Currently, no SRT intended for aerosolisation by nebulisation is available and 
additionally, previous studies recommended particle profiling in combination with formulation related 
to viscosity, whilst maintaining surface activity.56 Moreover, synthetic surfactant hold advantages that 
include large reproducibility with no need for harvesting and extraction of surfactant from animal tissue. 
Published information regarding particle size profile and surface tension lowering activity of natural 
and synthetic pulmonary surfactants, pre- and post-nebulisation, is limited. Our aim with this study was 
to investigate the biophysical properties of respirable particles generated with the use of an 
Aeroneb®Pro vibrating mesh nebuliser. To achieve this, the existing formulation of a novel synthetic 
pulmonary surfactant Synsurf® (in development) was changed by addition of surface active compounds. 
The analytical approach was based on the main considerations for the early development of inhaled 
drugs. This consists of properties i.e. particle profile (size), density, viscosity and surface activity which 
is influenced by composition and aerosol device used. A summary of methods used in this study is 
shown in Figure 3.3.  
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It is known that changes in PS composition influence biophysical properties. An example of this is 
displayed in pneumonia where interactions of bacteria and/or endotoxins (in Type II cells) influence the 
density and surface tension with a marked decrease in palmitic acid (PA) content within the PS.86 
Limited information is available with regards to the specific density of PS at varying PL concentrations. 
However, in comparison to pure DPPC preparations and bronchoalveolar lavage fluid, Synsurf® and 
the other natural surfactants fall within the expected range.87,88 Post-nebulisation most preparations 
showed a decrease in density, which is possibly due to the change lipid orientation. The addition of 
triacylglycerol and/or free palmitic acid increases the adsorption rate of PS and it is speculated that this 
is due to small defects induced in the membrane structure.29 In our experiments, only Synsurf® with PA 
or lower concentrations of cholesterol as well Curosurf® showed an increase in density post-
nebulisation. Although the density analysis used in this study is not ideal for detection of packing 
properties of lipid membranes, the increase in density of surfactant samples might indicate tighter 
(ordered) liposome structures generated during nebulisation.  
Preparation viscosity is of particular importance when developing an exogenous surfactant for 
nebulisation as this may influences the device selection, mist/aerosol density and uniform distribution.1,3 
Additionally, atomisation of liquids with higher viscosities has shown to be less efficacious, which 
might lead to an increased loss of surfactant preparation. However, increased viscosity is also linked to 
an increase in aerosol particle size using jet nebulisers.89 Our study showed no apparent link between 
viscosity of surfactants and particle size generated post-nebulisation. This might be attributed to the use 
of a vibrating mesh nebuliser, which generates less change in temperature during operation in 
comparison to jet- and ultrasonic-nebuliser.11,89 Although additions to Synsurf® increase the viscosity 
of preparations, cholesterol shows a concentration depended increase in viscosity, which was reinforced 
with the addition of PA. Due to the complex mixture of lipid and proteins/peptides of synthetic and 
natural surfactant, variations in viscosity is expected, possibly by aggregation of microstructures 
dispersed in the aqueous phase.90 Previous studies conducted with Survanta® (contains additional PA 
and triPA) and Infrasurf® (containing 5 % cholesterol), showed a PL concentration and temperature 
dependent increase in viscosity. These studies suggested that the combination of PA and triPa will 
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increase the viscosity of surfactant samples by preferential interaction with saturated lipids (DPPC). 
This contrasts with our viscosity findings of Synsurf® with palmitic acid and tripalmitin. However, 
Survanta® and other preparations mentioned were analysed at higher temperatures (± 35°C to 37°C) and 
contained higher fractions of unsaturated lipids.90 On the other hand Curosurf® and Liposurf® showed 
much lower viscosities in comparison to Synsurf® samples. This could possibly be attributed to the 
calcium chloride buffer solution used in Liposurf® preparations91, as the addition of calcium influence 
the formation of microstructures by increasing the protein-mediated PL aggregation within this lung 
surfactant.90 This aggregation and/or clustering of lipids previously induced by polymers is linked to a 
decrease in viscosity.92 Furthermore, Curosurf® is suspended in a sodium chloride solution and neutral 
lipids (which includes cholesterol and triacylglycerol) are removed by liquid-gel chromatography 
during manufacturing.49 Moreover, the dilution of PL’s from 80 mg/mL to 20 mg/mL, in our 
experiments might explain the lower viscosity of this surfactant preparation. Although the viscosity 
analysis method used in this study is designed for sperm samples93, filling times of Leja® slides 
converted to cP, provided substantial differentiation between inter-formulation of preparations that 
indicate morphological and rheological changes are induced by additional surface-active molecules. 
Moreover, none of the formulations displayed clogging/blocking of the micro-mesh within the 
Aeroneb®Pro nebuliser, which is a main concern with surfactant formulations intended for 
nebulisation.11 
Nebulised formulations of Synsurf® (with the exclusion of Syn 6), Liposurf® and Curosurf® showed 
particle generated below the recommend range (1000 d.nm to 3000 d.nm) suggested for optimal 
peripheral lung deposition.11,12,66 This indicates a clear disruption of liposomes within all preparations 
during aerosolisation. However, it must be noted that Synsurf® preparations underwent an 
ultrasonification step to disrupt large multimellar vesicles, that was not done for Curosurf® or Liposurf® 
purchased from the manufactures. Moreover, extrusion of Synsurf® preparations, showed a reduction in 
the change of particle diameters post-nebulisation, most within the recommend range. Previous studies 
have indicated that extrusion pre-nebulisation through larger filters (i.e. >1 µm in diameter) may 
contribute to the stability of vesicles within solution.78 Thus extrusion might increase the robustness of 
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liposomes, and maintain larger liposomes post-nebulisation as shown in Table 4.6. However, the 
addition of palmitic acid and tripalmitin appeared to aid in the preservation of particle diameter without 
extrusion, possibly by resisting disruption and penetration of PA into multimellar aggregates. This could 
affect packing and increase triPA interaction with DPPC.90  
It is important to note that the recommend range of particle diameters is based on mechanically 
ventilated infants and insufficient deposition is credited to low tidal volumes and functional residual 
capacity and high respiratory rates in combination with small airway diameters. This leads to a decrease 
in particle residence and a diminished deposition pattern of inhaled PS in the lower regions of the infant 
lungs.66 However, previous studies have indicated that nebulised Curosurf® administered by nasal CPAP 
was effective with smaller particles ranging from ± 800 d.nm – 900 d.nm.94 Thus deposition could be 
composition/formulation specific and smaller particles could provide optimal deposition. However, due 
to a paucity of clinical data in infants, hydrodynamic and aerodynamic particle size analysis can provide 
information curtailing the development in SRT for IRDS, but additional animal studies should be 
conducted.  
The rate of surface film formation of surfactant preparations was observed over a period of 900 seconds. 
Most surfactants showed a decline in ability to reduce interfacial surface tension post-nebulisation. 
However, Synsurf® 1 and 6 (PA and triPA) maintained surface-activity pre-nebulisation. Additionally, 
Synsurf® 5 cholesterol (at 1 %) and 6 (PA and triPA) showed an overall greater decrease in surface 
tension pre- and post-nebulisation. This possibly depicts an increase in overall interfacial adsorption 
rate which is of more significance to illustrate how effectively lipid molecules adsorb at the air–liquid 
interface to form the surfactant film. Clinically, fast adsorption is crucial as the surfactant film 
(monolayer) must be formed rapidly during the initial opening of the lungs.95 Extrusion, with either         
5 µm or 12 µm filter, did not change the surface tension reduction properties over the observation 
period, thus no changes in adsorption properties was detected. Synsurf® 2 with only PA was inferior to 
Synsurf® 6 (with the addition of PA and triPA). This observation is supported by previous studies, which 
concluded that the most effective synthetic surfactant preparation (with regards to surface activity) 
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consisted of DPPC, PG, PA, triPA and hydrophobic surfactant protein.96  The addition of cholesterol to 
Synsurf® enhanced surface adsorption at lower concentration (1 %), but showed a diminished effect 
when added in higher concentration (2 %). Previous studies using bovine surfactant showed hampering 
of adsorption at 25°C when cholesterol was removed however, this was not observed at higher 
tempratures.97 This might indicate differences due to the lack of surfactant proteins in Synsurf®. 
However, additional analyses at 37°C will have to be conducted.   
 
In conclusion, this study evaluated the biophysical properties and surface tension reduction ability of 
Synsurf® preparations in comparison to natural surfactants. Through the combination of analytical 
methods, we showed that extrusion of Synsurf® 1 as well as addition of cholesterol (1 %) or tripalmitin 
and PA, is beneficial to formulate the PS into an aerosol of respirable particles in the size range of           
1 µm -3 µm. In addition, PA/triPA inclusion in Synsurf® led to an overall better conservation of surface 
tension and ideal particles sizes with the vibrating mesh nebuliser. Liposurf® and Curosurf® did illustrate 
an overall greater decrease in surface tension over the observation period, with lower viscosities (as 
recommended for nebulisation) however, these natural surfactants did not generate particles within the 
recommended range when nebulised with a vibrating mesh nebuliser, under the same conditions as 
Synsurf®. 
Finally, this study has shown that the biophysical properties of Synsurf® 1 remains intact pre- and post-
nebulisation, a result that merits animal model investigation to establish its efficacy during 
aerosolisation. In addition to this, aerosol delivery of Synsurf® 1 may contribute to its use as a potential 
carrier of drugs to the air-liquid interface in airways.   
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APPENDICES/ADDENDUM A 
This study presented in part and in its entirety at a Stellenbosch University based academic year 
day and national conferences.  
1. 59th Academic Year day, Medicine and Health Sciences, Stellenbosch University: Held at 
Tygerberg Campus, Western Cape hosted by Stellenbosch University on the 13th of 
August 2015. 
 Abstract Title: Poster 
 Development of experimental compositions for aerosolisation of a synthetic pulmonary 
surfactant Synsurf®: Biophysical properties and effect of cholesterol on phospholipid-protein 
mixtures.  
 C Agenbag1, JM Van Zyl1, J Smith2 
2. SASBCP and TOXSA Congress held at The Wits Club, Johannesburg on the 31st August 
until 2nd September 2015.  
 Abstract Title: Oral Presentation 
 Development of experimental compositions for aerosolisation of a synthetic pulmonary 
surfactant Synsurf®: Biophysical properties and effect of cholesterol on phospholipid-protein 
mixtures. 
 C Agenbag1, JM Van Zyl1, J Smith2 
3. All African Congress on Pharmacology and Pharmacy held at Misty Hills Hotel, Gauteng 
on the 5th to 8th of October 2016.  
 Abstract Title: Poster 
 Biophysical Properties of Experimental Compositions of a Synthetic Pulmonary Surfactant 
Synsurf® For Aerosolisation. 
 C Agenbag1, JM Van Zyl1, J Smith2 
4. 61st Academic Year day, Medicine and Health Sciences, Stellenbosch University: Held at 
Tygerberg Campus, Western Cape hosted by Stellenbosch University on the 30th of 
August 2017. 
 Abstract Title: Poster 
Biophysical Properties of Experimental Compositions of a Synthetic Pulmonary Surfactant 
Synsurf® For Aerosolisation. 
C Agenbag1, JM Van Zyl1, J Smith2 
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